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The blood-brain barrier (BBB), which protects the central nervous system (CNS) from 
unnecessary substances, is a challenging obstacle in the treatment of CNS disease such as 
Parkinson’s Disease (PD). Many therapeutic agents such as hydrophilic and macromolecular 
drugs cannot overcome the BBB. One promising solution is the employment of polymeric 
nanoparticles (NPs) such as poly (lactic-co-glycolic acid) (PLGA) NPs as drug carrier. Over the 
past few years, significant breakthroughs have been made in developing suitable poly (lactic-co-
glycolic acid) (PLGA) and poly (lactic acid) (PLA) nanoparticles for drug delivery across the 
BBB.  
Recent advances on PLGA/PLA NPs enhanced neural delivery of drugs were reviewed 
and presented in the second chapter of the thesis. Both in vitro and in vivo studies were included 
in the review. From this review, it was learned that cellular uptake and therapeutic efficacy of 
drugs delivered with modified PLGA/PLA NPs were enhanced compared to free drugs or drugs 
delivered by unmodified PLGA NPs; no significant in vitro cytotoxicity was observed for PLGA 
NPs and PLA NPs. Surface modification of PLGA/PLA NPs by coating with 
surfactants/polymers or covalently conjuged with targeting ligands has been confirmed to enhance 
drug delivery across the BBB. Most unmodified PLGA NPs showed low brain uptake (<1%), 
which confirms the safety of PLGA/PLA NPs used for other purposes than treating CNS diseases.  
For the second part of the thesis, wheat germ agglutinin (WGA), a lectin was conjugated to 
PLGA nanoparticles (PLGA-tWGA NPs, 221 nm) to improve DAergic neuron delivery in 
C.elegans. PLGA-tWGA NPs did not show a significant effect on pumping rate and life span of C. 
elegans at low concentration (<3 mg/ml). Fluorescent studies of GFP-DAergic neurons revealed 
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that pumping rate and area of GFP-DAergic neurons of worms treated with a high concentrations 
PLGA-tWGA NPs (>3mg/ml) was significantly decreased. Number and mean intensity of GFP-
DAergic neurons also decreased, but no significant difference was found compared with control 
group. Co-localization of the fluorescent particles with the GFP-DAergic neurons of treated 
worms proved the targeting property of PLGA-tWGA nanoparticles to DAergic neurons. 
Enhanced targeted delivery of PLGA-tWGA NPs to neurons compared with tWGA and PLGA-t 
NPs confirmed that PLGA-tWGA NPs had the potential to act as targeted neural delivery systems 


















CHAPTER 1.    INTRODUCTION 
 
1.1.    Parkinson’s disease  
It is estimated that about 1–2% of the population over 65 years suffer from Parkinson’s 
disease (PD), the second most common neurodegenerative disease after Alzheimer’s disease 
(Alves, Forsaa et al. 2008). PD is a neurodegenerative disorder of the central nervous system, 
which impairs motor skills, cognitive processes, and other functions. Clinical symptoms of PD 
include both motor and non-motor symptoms such as bradykinesia, hypokinesia, and rigidity. 
These symptoms are known as Parkinsonism, which is essential for clinical diagnosis in PD. 
According to current studies, nigral dopamine deficiency-related dysfunction of the basal ganglia 




The cause of the disease however is unknown. PD’s symptoms result from the greatly 
reduced activity of dopamine-secreting cells while the cells in the pars compacta region of the 
substantia nigra die (Obeso, Rodriguez-Oroz et al. 2008). Pathologically, the disease is 
characterized by the accumulation of alpha-synuclein protein forming inclusions called Lewy 
bodies. The loss of function mechanisms in Parkinson's the brain cells are varied (Obeso, 
Rodriguez-Oroz et al. 2010). It is proposed that genetic mutations are not the only triggering 
factor of PD. “Pathogen theory” proposed by Braak’s group is somehow reasonable
 
considering 
the major gastrointestinal (GI) dysfunctions of PD patients and prevalence of PD in vegetarians 
(Ho, Woo et al. 1989). In this theory, it is proposed that an “unknown pathogen” penetrates the 
GI wall and enters the central nervous system (CNS) via retrograde transport through the the 
vagus nerve to cause PD (Braak, Rub et al. 2003). 
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Because dopamine cannot across Blood Brain Barrier (BBB), current treatments are 
effective at managing motor symptoms through the use of levodopa (L-DOPA), dopamine 
agonists and Monoamine oxidase B (MAO-B) inhibitors (Schapira 2005). However, drug 
delivery to the brain remains limited because of the blood-brain barrier (BBB). Take L-DOPA as 
an example, only 5-10% of L-DOPA orally administered is able to cross the blood-brain barrier. 
The remaining is often metabolised to dopamine by enzymes, i.e. decarboxylases, in the stomach 
or blood, causing a wide variety of side effects, such as nausea, dyskinesias and stiffness (Factor 
2008).  
To reduce the harmful side effects of drug such as L-DOPA associated with systemic 
accumulation, improved delivery systems must be developed for treatment of PA. Among the 
advanced technology, nanotechnology appears promising in developing drug delivery systems of 
targeting and controlled-release characteristics beneficial for drug delivery (Linazasoro 2008). 
1.2.    Nanoparticles as drug delivery vehicles 
The advantages of nanoparticles as drug delivery systems include time controlled drug 
delivery, reduced drug toxicity, improved bioavailability and enhanced therapeutic efficacy and 
biodistribution (Ravi Kumar 2000). Nanoparticles can also protect the sensitive drugs from 
degradation by environmental factors such as stomach acid and enzymes (Jores, Mehnert et al. 
2004). Polymeric nanoparticles range in size from about 10-1000nm (Kreuter 2001), and can be 
modified with different ligands such as antibodies to create a smart targeting delivery system. 
Polymeric nanoparticles of a size around or less than 300 nm coated with surfactants have been 
proved to be able to transport drugs across the BBB (Schroeder, Sommerfeld et al. 1998).  
Poly (lactic-co-glycolic acid) (PLGA) is a copolymer which is used in a host of Food and 
Drug Administration (FDA) approved therapeutic devices. It is synthesized by means of random 
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ring-opening co-polymerization of two different monomers. PLGA is a common-used 
biodegradable polymer as its degradation by hydrolysis in the body produces the original 
monomers, lactic acid and glycolic acid which are by-products of various metabolic pathways. 
The degradation time of PLGA is controlled by the ratio of the two monomers: the higher the 
content of glycolide units, the less time required. However, the copolymer with 50:50 monomers 
ratio exhibits the fastest degradation. Because of its minimal toxicity and ability of controlling 
the release of the drug, PLGA is suitable for drug delivery (Astete and Sabliov 2006). PLGA 
nanoparticles are versatile among nanopariculate systems because of their biocompatibility for 
drug targeting at the cellular level (Mohamed and van der Walle 2008). 
During the formation of the PLGA nanoparticles, L-DOPA is encapsulated within the 
polymer matrix and it is released upon degradation. Thus, the side-effects of the drug would be 
reduced as noted with conventional oral delivery systems (Pillay, Pillay et al. 2009). 
 In addition, to further improve the delivery efficacy of L-DOPA; a targeted drug system 
is designed by conjugating PLGA with the lectin: wheat germ agglutinin (WGA).  
1.3.  Lectins 
Lectins are sugar-binding proteins or glycoproteins that are highly specific for reversible 
binding to sugar moieties. Lectins were discovered by Peter Hermann Stillmark working with 
castor bean extracts 100 years ago. Lectins are found throughout nature, in plants (i.e. legumes, 
seeds, nightshades, grains, wheat, and nuts) and other foods such as dairy food, as well as in 
insects, and the human body (Kennedy, Palva et al. 1995; Bies, Lehr et al. 2004; Sharon and Lis 
2004).   
Carbohydrates acting as structural components of the human body are widely distributed in 
tissues especially on the cell surface, and are involved in diverse biological processes such as cell 
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adhesion, inflammation, cell activation (Bies, Lehr et al. 2004; Sharon and Lis 2004). These 
carbohydrates display specific sugar moieties for binding different kinds of lectins. Lectins are 
hardy proteins; they are resistant to stomach acid and digestive enzymes. Moreover, they can 
bind to gut wall, damage the epithelial cells, change gut permeability, pass through the gut into 
general circulation with other non-lectin proteins, and cause allergic reactions (Ni and Tizard 
1996). Thus, some plant and animal lectins are severely toxic to humans.  
It is their specific binding ability that makes nontoxic lectins suitable as pro-drug entities; 
lectins have been conjugated with drugs to enhance drug absorption in the gastrointestinal tract 
or to target drug to a certain kind of cells including intestine cells, cancer cells and brain 
endothelial cells (Bies, Lehr et al. 2004). Chunxia Wang’s group has designed wheat germ 
agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to 
colon cancer cells. Conjugated PLGA nanoparticles demonstrated 1.67 fold in the Caco-2 (30% 
of uptake) and 1.48 fold HT-29 (40% of uptake) cells more than non-targeted nanoparticles 
(Wang, Ho et al. 2010). Xiaoling Gao et al. developed an enhanced delivery of vasoactive 
intestinal peptide with nanoparticles conjugated with wheat germ agglutinin (Gao, Wu et al. 
2007). The delivery of incorporated vasoactive intestinal peptide by PLGA nanoparticles and 
WGA conjugated PLGA nanoparticles was greatly improved 3.5 to 4.7 folds and 5.6 to 7.7 folds 
respectively when compared to the free drug. Wen Z. et al conjugated odorranalectin (OL) to 
PEG-PLGA nanoparticles to improve nose-to-brain drug delivery in the treatment of central 
neuron systems disorders(Wen, Yan et al. 2011). 
Targeting delivery is a key challenge in PD therapy. Many severe side effects induced by 
the undesirable distribution of any antiparkinsonian drug in health tissues greatly limits the 
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maximal allowable dose of the drug. If the non-pathogenic lectins can deliver drugs to the 
nervous system, the dosage of the drugs may be minimized, and its side effects reduced. 
   Various lectins have been used as components of oral drug delivery systems including 
tomato lectin, peanut agglutinin and wheat germ agglutinin (WGA) (Gao, Wu et al. 2007). WGA 
comes from Triticum vulgaris, and shows a special affinity to N-Acetyl-glucosamine (GlcNAc) 
and sialic acid which are the major glycoproteins on the surface of most cells. WGA is regarded 
as a promising carrier for oral drugs because of its biochemical characteristics and non-toxic 
property(Irache, Durrer et al. 1994).   In solution, wheat germ agglutinin exists as a heterodimer 
with a molecular weight of approximately 38,000 daltons, normally cationic under physiological 
conditions. The uptake and anterograde axonal transport of WGA has been confirmed in prior 
work (Margolis, Marchand et al. 1981).  
1.4. Caenorhabditis elegans 
Caenorhabditis elegans (C.elegans) is a 1 mm long, transparent nematode (Wintle and Van 
Tol 2001) of several advantages for laboratory study including short generation time (3.5 days), 
and ease of growth which allow for rapid and inexpensive production of animals (Wood 1988). C. 
elegans, with a simple, well characterized nervous system consisting of 302 neurons, is a useful 
model organism for the study of neuron systems (Albeg, Smith et al. 2011). It is found that the 
human genome contains only 20% more genes that the C. elegans genome according to the 
completion of the C. elegans genome and those of mouse and human (Hillier, Coulson et al. 
2005). In addition to the genome, the worm’s neurons contain almost all the known signaling and 
neurotransmitter systems found in vertebrates, including different molecular pathways involved 
in the production of numerous neurotranmitters such as glutamate, acetylcholine, and dopamine 
(DA)
 
(Bargmann 1998; Nass and Blakely 2003). 
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C.elegans is a model commonly used to study neuron drug delivery (Braungart, Gerlach et 
al. 2004; Nass, Merchant et al. 2008) as the hermaphroditic C.elegans organism contains only 
eight dopamine neurons, thereby largely simplifying a wide array of investigations (Nass, Hall et 
al. 2002). Worms that express the green fluorescent protein (GFP) can be used when the in vivo 
visualization of cellular processes is necessary. Other advantages of using C.elegans in 
laboratory studies include a short generation time, and ease of growth (Wood 1988; Riddle 1997; 
Wintle and Van Tol 2001).  
1.5. Objectives 
1. Conduct and write a review paper on PLA/PLGA nanoparticles for delivery of drugs 
across the blood-brain barrier. 
a)  Assessment of cytotoxicity, cellular uptake, and therapeutical efficacy of PLA/PLGA 
nanoparticles in vitro. 
b)  Investigation of brain uptake, location in the brain, and therapeutical efficacy of 
unmodified and modified PLA/PLGA nanoparticles via systemic administration with rats 
or mice in vivo. 
2. Development of WGA conjugated PLGA nanoparticles for enhanced neuron delivery in 
C.elegans. 
a)  Synthesis of TRITC conjugated poly (lactide-co-glycolide) nanoparticles (PLGA-t 
NPs) and tWGA conjugated PLGA nanoparticles (PLGA-tWGA NPs) by emulsion 
evaporation method, with PVA as surfactant. 
b)  Charaterization of PLGA-t NPs and PLGA-tWGA NPs in terms of size, size 
distribution, zeta potential (DLS), morphology (TEM) and conjugation efficiency. 
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c)  Analysis of the effect of tWGA, PLGA-t NPs and PLGA-tWGA NPs on pumping rate, 
size, and number, intensity and area of GFP-DAergic neurons with C.elegans. 
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CHAPTER 2.     PLA/PLGA NANOPARTICLES FOR DELIVERY OF 
DRUGS ACROSS THE BLOOD-BRAIN BARRIER: A REVIEW 
2.1. Introduction 
Treatment of central nervous system (CNS) diseases including Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease, schizophrenia, HIV infection of the brain and brain 
tumors remain limited due to the low transport of drugs across the blood-brain barrier (BBB) 
(Wohlfart, Gelperina et al. 2011). The BBB is composed of special endothelial cells with tight 
junctions, pericytes, astrocytes and microglial cells (Begley 2004); tight junctions (TJ) are 
formed by complex network of proteins and linked with cytoskeleton to restrict passage of 
substance from bloodstream to the brain (Chen and Liu 2011).  
Only a small amount of water-soluble molecules diffuse paracellularly through the TJ. 
Small lipid soluble molecules enter transcellularly through the lipid membrane. Cell-mediated 
transcytosis is another recently identified route for entering the brain through the BBB; for 
example, some pathogens such as HIV or Cryptococcal could enter the BBB via cell-mediated 
transcytosis (Park 2008; Chen and Liu 2011). For other substances, adsorptive transcytosis and 
specific receptor-mediated are the main transport routes across the BBB (Chen and Liu 2011). 
Adsorptive-mediated transcytosis (AMT) is induced by the interaction between the negatively 
charged membrane surface and a positively charged substance. Receptor-mediated transcytosis 
(RMT) is a selective uptake of a specific substance. The expression of different transporters such 
as transferring receptors, insulin receptors, and lipoprotein receptors could help the 
internalization of molecules (Chen and Liu 2011).  
Many therapeutic agents for CNS disease such as hydrophilic drugs and macromolecular 
drugs cannot transport through the impermeable tight junctions of the BBB (Mistry, Stolnik et al. 
2009). Therefore, invasive and non-invasive methods were employed to enhance brain delivery 
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of drugs. Compared to invasive methods which include changing the permeability of the BBB, or 
direct intracerebral infusion and implantation of the drug, non-invasive methods such as systemic 
administration are preferred (Wohlfart, Gelperina et al. 2011).  
For systemically administered drugs, the goal for the drug delivery system is to cross the 
BBB in sufficient concentrations without a negative impact on the function of the BBB. A 
number of drug carriers have been developed to improve brain delivery of drugs, and among 
carriers, nanoparticles (NP) have been receiving an increased attention because of their unique 
properties (Chen and Liu 2011). Biodegradable polymeric nanoparticles, as a stable drug carrier 
have been well studied for drug delivery. The advantages of polymeric nanoparticles as drug 
delivery systems include time controlled drug deliver, reduced drug toxicity, improved 
bioavailability, and enhanced therapeutic efficacy of the entrapped drug (Patel, Zhou et al. 2011). 
Brain delivery can be achieved by well-designed and modified polymeric nanoparticles. Blank 
polymeric nanoparticles are fabricated from polymers such as poly (lactic-co-glycolic acid) 
(PLGA) with surfactants such as poly (vinyl alcohol) (PVA) and others as stabilizer. 
Characteristics of polymeric nanoparticles such as size, zeta potential and hydrophilicity can be 
controlled by surface modification such as surfactant coating to enhance brain uptake. In addition, 
ligands known to target BBB surface receptors such as transferring, insulin, and lipoprotein 
receptors can be linked to the surface of the polymeric nanoparticles to provide targeted brain 
delivery and improved nanoparticles uptake (Rip, Schenk et al. 2009).  
Both in vitro and in vivo studies have been conducted to study cytotoxicity and 
effectiveness of polymeric nanoparticles designed for delivery of drugs to the CNS. Prior to 
complex and expensive in vivo studies, in vitro studies on cytotoxicity, cellular uptake, 
endocytosis mechanism, and drug efficiency of drug delivery system were investigated with 
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different cell lines such as brain endothelial cells and glioma cells. Next, in vivo studies 
performed on mice and rats were used to study brain uptake, location of nano carriers and 
therapeutic efficacy of the entrapped drug. 
Aspects of nanoparticle synthesis, general properties, mechanisms of action and potential 
pitfalls of nanoparticles for drug delivery to the central nervous system have been reviewed over 
the past years (Kreuter 2001; Olivier 2005; Roney, Kulkarni et al. 2005; Silva 2007; Wohlfart, 
Gelperina et al. 2011). Recent findings on polymeric nanoparticles, as brain delivery carriers are 
available in the literature as well (Patel, Zhou et al. 2011; Costantino and Boraschi 2012). 
However, to the authors’ knowledge, no reviews have been specifically and solely dedicated to 
the effect of nanoparticle properties on delivery of drugs to the brain with PLGA/PLA 
nanoparticles; this aspect was only partially mentioned or briefly discussed in the previous 
review papers. The goal of this review is to highlight the recent developments on PLGA or poly 
(lactic acid) (PLA) nanoparticles designed for neural delivery, with emphasis on nanoparticle 
cytotoxicity, therapeutic efficacy of the entrapped drug, and brain uptake of PLGA and PLA 
nanoparticles as a function of their properties.  
In this review, a literature search was conducted on the subject of PLGA/PLA NPs and 
brain delivery of drugs using PubMeb, ScienceDirect and Springerlink databases. The following 
key words were used in the search: polymeric/PLGA nanoparticles, brain delivery, blood-brain 
barrier, central nervous system, and neuron delivery. Relevant papers were selected based on 
whether it is PLGA/PLA NPs and systemic administration with the goal of delivering drugs 
across the BBB. In total, 29 papers on PLGA/PLA nanoparticles for drug delivery across the 
BBB were used in this review.  
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The papers are summarized with an emphasis on NP characteristics (core polymer, 
emulsifier, surface modification, loaded drug, size, zeta potential), the in vitro and in vivo models 
used, methods, and significant findings. The information is compiled in Table 2.1. The 
discussion section following the summaries is divided into two sections: in vitro studies and in 
vivo studies. For the in vivo studies, the percentage (%) brain uptake over 24 h was calculated as 
percentage of dose administered per animal, and plotted versus time (h). Potential effects of 
nanoparticle properties such as size, dose and administration on brain uptake of different 
nanoparticles were compared and discussed.  
2.2. Summaries of cited papers 
Tsai, Chien et al. (2011): 
The tissue distribution and BBB distribution of curcumin and PLGA nanoparticles 
entrapped with curcumin (C-NPs) (163 nm) in all organs and regions of the brain in rats were 
studied. After intravenous administration of 25 mg/kg of free curcumin and C-NPs in male 
Sprague-Dawley rats, a 500 μl blood sample was obtained at 15, 30 and 60 min. The organs 
tested including liver, heart, spleen, lung, kidney and brain were removed, and the brain was 
dissected. Free curcumin distributed more in liver (9.0 min µg/ml) and kidney (12.0 min μg/ml) 
than in other organs, indicating that it might be cleared and metabolized. When curcumine was 
administered as C-NPs, a significant amount of curcumin was found in the spleen and lung 
instead of liver and kidney, which implied that NPs helped to provide a more efficient 
distribution to organs than free curcumin. Both formulations were able to cross the BBB whereas 
C-NPs showed significantly higher distribution than free curcumin. The significantly increased 
half-life (t1/2/min) and mean residence time (MRT/min) confirmed that PLGA NPs prolonged the 
retention time of curcumin in the cerebral cortex and the hippocampus by 2.0 and 1.8-fold 
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respectively, while no significant difference was found in the other brain regions (Tsai, Chien et 
al. 2011) 
Mittal et al. (2011): 
Oral delivery of estradiol to the brain in rats was evaluated for Tween 80 (T80) coated 
PLGA nanoparticles synthesized with different concentration of initial T-80 concentrations. Five 
concentrations of T80 (T1-T5, 1%, 2%, 3%, 4% and 5%, v/v to total suspension volume) were 
coated on the PLGA NPs surface with Didodecyl dimethyl ammonium bromide (DMAB) as 
emulsifier to form NPs with a size range of 138 nm to 172 nm. The integrity of the coating was 
evaluated at 2 h for simulated gastric fluid (SGF) and 6 h for simulated intestinal fluid (SIF) to 
evaluate stability of T80 coating at pH 1.2 and at pH 7.4. The percentage of remaining T80 
coating for T1- and T5-NPs in SGF was 77.3% and 43.7%, while the percentage of that in SIF 
was 65.6% and 37.8% respectively. T1- and T4-coated PLGA nanoparticles (138 nm, 157 nm 
respectively) were selected for the oral administration in rats to observe the effect of T80 coating 
concentration on uptake. After oral administration in male Sprague-Dawley rats for 24 h, PLGA 
nanoparticles coated with 4% T80 showed more effective delivery of estradiol to rat brain (1.969 
±0.197 ng/g tissue) as compared to uncoated NPs (1.105 ±0.136 ng/g tissue), and almost similar 
level of brain estradiol as that achieved by intramuscular administration of same dose (200 µg/rat) 
of free drug (2.123 ±0.370 ng/g tissue). Two behavior tests were performed in an ovariectomized 
(OVX) rat model of Alzeimer’s disease (AD) including an open field test which used to evaluate 
the motor functions of the rats, and elevated plus maze test which was used to measure fear or 
anxiety. The tests were carried out after 6 weeks of treatment with T80-PLGA NPs. Behavior 
tests showed that the NP treatment effectively attenuated the anxiety-related behavior of the rats 
over the sham (control) group.  
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Table 2.1 Summaries of NP characteristics (core polymer, emulsifier, surface modification, loaded drug, fluorescent marker, 
















Animal study Result Ref 
PLGA PVA    Curcumin   163 -12.5 
In vivo: Male Sprague-
Dawley rats, i.v. 
administration 
Significantly increased retention 
times of curcumin in the cerebral 
cortex and hippocampus 








In vitro: simulated 
gastric fluid and 
intestinal fluid 
T-80 coat was stable in simulated 
gastric gluid and intestinal fluid 
Mittal, 
Carswell et al. 
2011 
1% T80                  138.8 
19.2,  
pH 5.6 
2% T80   141.8 
7.7,  
pH 7.2 
3% T80    153.1 
-1.1, 
 pH 7.2 In vivo: male sprague-
Dawley rats, oral 
administration 
(1%,4% T80-NPs); 
i.v. (1% T80-NPs) 
Orally administrated T-80 coated 
nanoparticles reached higher levels 
after 24 h than uncoated drugs, and 
similar to those after same does of 
intramuscular drug injection   
4% T80   157 
-3.6,  
pH 7.2 




PVA   
doxorubicin 
  238.6 11.8 
In vivo: tumor-bearing 
male Wistar rats, tail 
vein injection 
Loperamide loaded PVA-stabilized 
PLGA nanoparticles coated with 
poloxamer proved the highest and 
longlasting anti-tumor(glioblastoma) 




PVA F68   243.4 6 
PVA T80     239.9 8.2 
HSA     401.7 9.5 
HSA F68   408.6 8.1 
HSA T80     412 16.2 
PVA   
loperamide 
  177.7 -11.4 
PVA F68   168.5 -17.9 
PVA T80     166.9 -25 
HSA     288.9 -11.9 
HSA F68   287.7 -17.5 
HSA T80     292.4 -18.9 
PLA 
        162.1 -29.5 
In vivo: mice, tail vein 
injection 
T80 coat was necessary for brain 
targeting. Free FITC, T80  and blank 
NPs were not observed in brain 
tissues 
Sun, Xie et al. 
2004 
      FITC-dextran  194.2 -13.4 






(Table 2.1 cont’d) 
PLGA 
PVA   
docetaxel   
227.7 -27.5 
In vitro: C6 glioma 
cell line,  cytotoxicity 
studies 
The lowest IC50 was achieved after 
72 h by the F68-PVA-NPs 
Kulkarni and 
Feng 2011 
TPGS   222.3 -41.3 
PVA F68 235.5 -23.8 
PVA T80   250.2 -21.3 
PVA F127 242.5 -22.4 
PVA   
  coumarin-6 
177 -31.1 
In vitro: MDCK cells 
uptake studies 
In vitro: TPGS coated PLGA Nps 
showed 1.5-fold higher cellular 
uptake than PVA-emulsified NPs. 
F68-coated PLGA NPs displayed the 
highest uptake compared with T80, 
F127 coated NPs. 
TPGS   165 -38.5 
PVA F68 196 -20.2 
PVA T80   194 -23.1 In vivo: male sprague-
Dawley rats, tail vein 
injection 
F68-coated PLGA nanoparticles also 
demonstrated highest brain 
accumulation over those with T80 
and F127 PVA F127 188 -20.6 
PLGA PVA 
  
  coumarin-6 
269.3 -21.2 




Carotid artery administration of all 
NPs showed higher brain distribution 
than those after jugular vein 
administration. T80-PLGA NP 
prolonged circulation time in the 
blood. CS-PLGA NP and T80-PLGA 
NP proved high brain distribution 
than uncoated and F68 coated NPs. 
CLSM studies demonstrated only 
T80-PLGA cross the BBB and 
located in the parenchyma. 
Tahara, 
Miyazaki et al. 
2011 
T80   231.7 -20.3 












173.5 -24.9 In vitro: rat brain 
endothelial cell and 
C6 co-cultures 
P188-coated NPs showed better 
permeability than P80-coated NPs 
(1.47 fold); no toxicity  




  152.3 -0.5 
P80 149 1.5 In vivo: male ICR 
mice, tail vein 
injection 
Hot-plate test and formalin test for 
the antinociceptive effects studies. 
P188 NPs showed better effect over 
P80 NPs followed by PEP NP and 
blank NP P188 147 3.1 





224.2 -22.4 In vivo: male SD rats, 
tail vein injection P188-coated NPs distributed more in 
the brain than P80-coated NPs. 
Surfactant-coated NPs showed 
enhanced brain delivery over 
uncoated; pegylated NPs showed 




  196.5 -0.4 
P80 190 1.2 
 PLGA-PEG-
PLGA 




(Table 2.1 cont’d) 
PLGA 
    
  coumarin-6 
215 n/r 
In vitro: MDCK cells 




instead of coumarin-6) 
The additives of P80 and TPGS 
during synthesis helped to improve 
cellular uptake more than surface 
coated nanoparticles; P80 emulsified 
NPs showed lowest cell viability 
Xie, Lei et al. 
2010 
PEG   225 n/r 
TPGS   248 n/r 
P80   256 n/r 
F127   234 n/r 
  PEG 239 n/r 
  TPGS 245 n/r 




in B (AmB) 
  120 n/r 




Enhance the stability and entrapment 
efficiency. Brain targeting and cross 
the BBB 
Ren, Xu et al. 
2009 
T80     120 n/r 
PLGA TPGS  
  
  coumarin-6 
94.7 -22.3 
In vitro: cytotoxicity 
in SH-SY5Y cells by 
MTT assay 
no significant cytotoxic effects  






In vivo: CD-1 wild-
type mice, caudal 
veins injection 
Accumulated in the periventricular 
region of the cortex and the third 
ventricle, mechanism was 




  99.6 -18.3 In vivo: APP/PS1 
double transgenic 
mice, caudal veins 
injection 
behavior tests, senile plaque and 
biochemical parameters were 
confirmed superior to the blank NPs TMC   146.7 21 
PLGA TPGS       250 n/r 
In vitro: PC 12 cell 
line 
No cytotoxicity, the more TPGS on 











In vitro: Polarized 
MDCK cell 
monolayers 




et al. 2012 













sulpiride rodomine B 
218 -39 
In vivo: male Sprague 
Dawley rats, injection 
in caudal vein 
Faster clearance from the plasma and 
a high biodistribution in brain 
Parikh, 






BSA 308 n/r 
PEG-PLA   
  
  
coumarin-6 100 -16.8 In vitro: coculture of 
brain endothelial cells 
(BCEC) and astrocytes 
Permeability of CBSA-NPs was 
higher than blank NPs, and 
decreased while incubated with free 
CBSA Lu, Wan et al. 
2007 
BSA coumarin-6 97.4 -16.2 
CBSA  coumarin-6 105 
-13/-
12.2/-9 
In vivo: male BALB/c 
mice, tail vein 
injection 
absorptive mediated transcytosis 
(AMT) process while no brain 















In  vivo: Rat Brain 
Perfusion Technique; 
rat femoral vein 
injection  
Not able to cross the BBB, localized 
into the blood vessels 
Costantino, 














































Penetrate into cerebral parenchima 
PEG-PLGA n/r 
  
  coumarin-6 
109.3 -23.4 
In vitro: bEnd.3 cells, 
a model of the BBB 
Significantly higher bEnd.3 cells 
uptake and brain delivery 





In vivo: male nude 
mice intravenously 
infection 
Significantly higher brain delivery 
PLA PVA 
  3H-ritonavir   300 -19.3 





TAT-NPs showed 40-fold increasing 
uptake than free ritonavir, similar 
with unconjugated NP in MDCK-
MDR1 cells 






3H-ritonavir   340 2.4 
In vivo: male mice, tail 
veil injection 
800-fold higher brain ritonavir level 
than free ritonavir and 7-dold higher 
than unconjugated NP 
  coumarin-6 n/r n/r 
In vivo: male mice, tail 
veil injection 
Located within the parenchyma 
PLGA  F68 
SA-g7 loperamide   180 
-22.8,  
pH 7.4 
In vivo: male albino 
Wistar-Hannover rats, 
tail vein injection 
Significantly increase the central 
opioid activity of LOP for 24 h than 
other nanodelivery system 
Tosi, Vergoni 
et al. 2010 
g7 loperamide   155 
15.2,  
pH 7.4 






SA-g7 NPs can cross the BBB, 
prolonged retention time 























(Table 2.1 cont’d) 
PLGA PVA Tet-1 peptide curcumin   
150-
200 
-30 to -20 
In vitro: cytotoxicity  
on LAG cells; uptake 
on GI-1 glioma cells 
no significant cytotoxic effects; Tet-
1 conjugated NPs showed increased 
uptake compared to unconjugated 
NPs  
Mathew, 
Fukuda et al. 
2012 
PEG-PLGA n/r 
  paclitaxel   168 n/r In vitro: RG2 glioma 
cells 
Higher cytoxicity in RG2 cells due to 
increased microtubule stabilization 
than uncoated NP 
Geldenhuys, 




paclitaxel   237.6 n/r 







In vitro: coculture of 
brain endothelial cells 
(BCEC) and astrocytes 
Cellular endocytosis of Tf-NPs was 
20-fold greater than blank NPs; 2-
fold greater than BSA-NPs. T20-NPs 
showed strong toxicity 
Chang, Jallouli 
et al. 2009 
Tween 20 Dil 80.9 
-21.4,  
pH 7 










    coumarin-6 228.6 -30 
In vitro: C6 glioma 
cell line 
Increasing uptake; non-specific 
endocytosis pathway and active 
receptor-mediated Tf/TfR 
endocytosis 




  coumarin-6 245.8 -29 
In vivo: Male Sprague 
-Dawley rats, 
intravenous 
Much higher concentration of 
coumarin 6 in the brain than non-
conjugated NPs;  
  Docetaxel   121.6 -36.5 
In vitro: C6 cells 
Cell viability and TC50 were 
determined, Tf-TPGS-PLA showed 
most efficient drug delivery 
Transferrin 
(Tf) 






  112.9 -35.3 
In vitro: 8 human 
cancer cell lines of six 
different cancer tissues 
Tf-PEG-PLGA NPs and PEG-PLGA 
NPs showed higher cytotoxicity than 
PLGA NPs Jain, Chasoo et 
al. 2011 
PEG-PLGA 
    117.2 -4.2 
Transferrin 
(Tf) 
  121 -4.3 
Transferrin 
(Tf) 
  coumarin-6 n/r n/r 
In vivo: albino rats, 
i.v. administration 
Tf-PEG-PLGA was located within 











In vitro: HBMECs, 
cytotoxicity and 
permeability 
Tf and DODAB had effect on cell 
viability, and permeability of Tf-NPs 
with 67% DODAB reached highest 






In vitro: HBMECs, 
uptake 
Tf-PLGA NPs showed higher uptake 




(Table 2.1 cont’d) 
PEG-PLGA n/r 
      92 n/r 
In vitro: RG2 glioma 
cells 
Enhanced cellular uptake  compared 
to unconjugated NPs and free 
Tempol Carroll, Bhatia 




  coumarin-6 
105 n/r 
tempol   
More effective in preventing cell 
viability compared to unconjugated 
NPs and free Tempol 
PLGA PVA 
glycopeptide








-0.5 to -10 
In vitro: neurons/glial 
cultures 
PLGA NPs were not toxic. 
Glycopeptides conjugated NPs 
enhanced endocytosis  
Grabrucker, 








In vitro: NCAM1 
labeled microtubule 
associated protein 
positive cells and 
CD44 labeled glial 
cells 
NCAM-NPs targeted more to 








CD44-NPs targeted to glial cells 





      90 -24     
Hu, Shi et al. 
2011 lactoferrin 
  coumarin-6 95 n/r 
In vitro: bEnd.3 cells, 
a model of the BBB 
significantly increased uptake in 
bEnd.3 cells; Clathrin mediated 
endocytosis; low toxicity 
In vivo: KM mice, 
injection in caudal 
vein 
2.49 times of coumarin-6 
accumulation in the brain 
urocortin 
(UCN) 
  120 -14 
In vivo: 6-OHDA rats 
model of PD, injection 
in caudal vein 
Enhanced delivery and theraputical 
effect of UCN-Loaded Lf-NPs was 
proved 
In vivo: BALB/c mice, 
injection in caudal 
vein 
Transient acute dose-related 
inflammatory reactions in liver, 














  188 -28 





human astrocyte (HA) 
A higher grafting efficiency and a 
lower molecular weight of γ-PGA 
increased the peameability of SQV 
cross the BBB, enhance the 
endocytosis and expression of 
ornithine decarboxylase (ODC) 






, a DNA 
aptamer 
  coumarin-6 n/r n/r 
In vitro: C6 glioma 
cells 
Improved cellular association 





  121 -23 
In vitro: C6 glioma 
cells 
Enhanced cytotoxicity of AP 





  156 -32.9 
In vivo: rats bearing 




target brain tumor, improved drug 
efficacy and prolong the life span of 
rats bearing gliomas 
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Neuropathological examination of OVX rats proved that NPs treated groups prevented the 
expression of amyloid β-42 (Aβ42), which plays an important pathological role in AD 
development in the hippocampus region of brain (Mittal, Carswell et al. 2011). 
Gelperina et al. (2010): 
The efficacy of one nanoparticle delivery system is not only affected by the surface 
coating, but also by the core materials used in the NP synthesis such as stabilizer, drug and core 
polymer. Gelperina, S. et al compared doxorubicin/loperamide delivery to the brain using 
polysorbate 80 (Tween® 80, T80) or poloxamer 188 (Pluronic® F68) surfactant-coated PLGA 
nanoparticles. Two emulsifiers: poly (vinyl alcohol) (PVA) and human serum albumin (HSA) 
were used during synthesis, with HSA believed to be a safer surfactant. Tumor-bearing rats were 
prepared by tumor implantation to the adult male Wistar rats by injecting tumor cells into the 
cavity of the right lateral ventricle. The rats were treated for rat glioblastoma by using 
doxorubicin loaded NPs, administered by tail vein injection. PLGA/PVA coated with F68 (243.4 
nm) showed the most effective anti-tumor effect: long-term remission in 40% (4/10) of the 
treated animals. PLGA/PVA coated with T80 (239.9 nm) was not as effective as PLGA-F68, 
only one rat survived the treatment. The analgesic effect of loperamide loaded nanoparticles was 
evaluated in female ICR mice or female Balb/c mice after intravenous injection. Tail-flick test 
which measured nociceptive threshold of mice were performed, and the maximal possible effect 
(% MPE) was determined to evaluate the analgesic effect. PLGA/PVA+F68 loaded with 
loperamide (168.5 nm) proved the maximum and most long-lasting antinociceptive effect: 80% 
MPE 15 min after injection and was maintained at 70 % for at least 60 min. PLGA/PVA+T80 
provided a less prolonged analgesic compared to those with F68 (80% after 15 min and 40% 
after 60 min). Loperamide in solution of 1% F68 showed little effects while loperamide and F68 
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alone didn’t show any antinociceptive effect. PVA-stabilized PLGA nanoparticles coated with 
F68 proved to be a promising brain delivery of the drugs (Gelperina, Maksimenko et al. 2010).  
Sun et al. (2004): 
Polysorbate 80 (Tween® 80, T80) has been proven to display a specific role in brain 
targeting. FITC loaded T80 coated surfactant-free PLA nanoparticles (FITC-T80-NP) were 
prepared (202.6 nm). Surfactant-free NPs with FITC and T80-coated NPs were synthesized as 
control groups. About 45 min after administration of 0.2 ml to mice by tail vein injection, the 
vascular perfusion and brain fixation was performed. Fluorescence studies of the brain found 
FITC-T80-NPs mainly located at the wall of brain micro-vessel endothelial cells, and indicating 
that NPs crossed the BBB via endocytosis mechanism. No fluorescence was found in the brain 
for the T80-NP with FITC-dextran , FITC-NPs, or mixture of free FITC and free T80, which 
confirmed the role of T80 coating on nanoparticles in brain delivery (Sun, Xie et al. 2004).  
Kulkarni and Feng (2011)  
Both polyvinyl alcohol (PVA) and D-α-tocopheryl polyethylene glycol 1000 succinate 
(vitamin E TPGS) were used as emulsifier to prepare PLGA nanoparticles. Poloxamer 188 
(Pluronic® F68), polysorbate 80 (Tween® 80, T80) and poloxamer 407 (Pluronic® F127) were 
further coated on surface of PLGA NPs, and the effects of the surface modifications on the 
characteristics of the delivery system were investigated. The average diameters of all surface-
modified NPs loaded with coumarin-6 were below 200 nm, and that of all surface-coated NPs 
with entrapped docetaxel was in the range of 220-250 nm. The in vitro release study of 
coumarin-6 from surface-modified NPs which used PVA as an emulsifier revealed that less than 
10% of the coumarin-6 was released while 8% was released from TPGS NPs after incubation in 
10 mM PBS (pH 7.4) at 37°C for 24 h. The cellular uptake study of TPGS-emulsified and PVA-
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emulsified PLGA NPs performed on Madin Darby canine kidney (MDCK) cells proved that 
TPGS was a better emulsifier which enhanced 1.5-fold more cellular uptake efficiency compared 
to the PVA emulsified NPs after 2 h incubation. Surface coated PLGA NPs with F68, F127 and 
T80 showed enhanced cellular uptake (26%, 25%, and 21%) versus unmodified NPs, and F68-
modified PLGA NPs showed the highest uptake efficiency. The biodistribution study of surface 
modified PLGA NPs with entrapped coumarin-6 was carried out in rats 90 min after tail vein 
injection. The highest distribution was observed in the liver, lungs and spleen, and the 
percentages was: 29.9%, 34.9% and 18.4% for PVA-NPs; 1.19, 11.1 and 12.0% for TPGS-NPs, 
3.94, 7.84 and 13.8% for T80-PVA-NPs,  8.17, 15.8 and 27.2% for F127-PVA-NPs, and 6.01, 
7.84 and 11.2% for F68-PVA-NPs. TPGS-NPs also showed a higher distribution in the heart. It 
was demonstrated that surface functionalized PLGA NPs helped NPs reach the brain, and brain 
uptake of F68-PVA-PLGA was proved to be most efficient (6.29%) over NPs made with T80 
(4.26%), F127 (5.07%), TPGS (4.20%) and PVA only (2.59%). The confocal microscopic 
studies of the brain after 90 min intravenous injections of the surface-coated NPs with entrapped 
coumarin-6 were performed. The green fluorescence was observed in the brain of the surface-
coated NPs treated groups, which further confirmed surface-modified NPs delivered to the brain. 
The cell cytotoxicity of the docetaxel-loaded PLGA NPs coated with different surfactants was 
studied with the C6 glioma cell lines. The cell viability was determined after incubation for 24, 
48 and 72 h. Cells exposed to drugs entrapped in the nano-delivery system showed lower 
viability than those exposed to free drug. Furthermore, IC50, the concentration of the drug 
required to kill 50% cells in a fixed time period was determined to compare the drug delivery 
efficiency of different formations. The lowest IC50 in C6 glioma cells after 72 h was achieved by 
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the F68-PVA-NPs, which was 86.51 and 98.58% more efficient than that of PVA-NPs and free 
drug (Kulkarni and Feng 2011). 
Tahara et al. (2011): 
Efficacy of brain targeting with polysorbate 80 (Tween® 80, T80), poloxamer 188 
(Pluronic® F68) and chitosan (CS) modified PLGA NPs (215 nm, 252 nm and 396 nm) was 
studied. In vivo studies were conducted in male Wister rats by left carotid artery or left jugular 
vein administration of 100 mg/ml NPs with coumarin-6 as fluorescence probe in different 
volumes (0.05, 0.10, 0.25 mL). The clearance of F68-NP from blood was faster than unmodified 
NPs, and the retention time of T80-NP was prolonged compared to other NPs for the carotid 
artery injection. Carotid artery administration was proved to be a more effective way of 
delivering all NP types into the brain, compared to jugular administration. Amount of NPs in the 
brain was quantified after 60 min administration via carotid artery, and brain slices were 
observed using confocal laser scanning microscopy (CLSM). T80-PLGA and CS-PLGA NPs 
accumulated more in the brain than uncoated and F68-coated PLGA NPs. CLSM of brain proved 
that T80-PLGA NP crossed the BBB, while CS-PLGA NP mainly adhered to endothelial cells. 
Most uncoated and F68-PLGA NP remained in the blood vessels, and very small amounts 
transported to the parenchyma (Tahara, Miyazaki et al. 2011). 
Chen et al. (2011):  
Chen Y.C.’ group developed poloxamer 188 (P188) or polysorbate (P80) coated PLGA-
PEG-PLGA nanoparticle delivery systems for brain delivery of loperamide. A novel PLGA-
PEG-PLGA triblock copolymer was used and TPGS served as emulsifier for the preparation of 
the nanoparticles. The in vitro studies of loperamide loaded nanoparticles were carried out in rat 
brain endothelial cell line (RBE4) and C6 cells co-cultures after 4 h incubation at 37 ◦C. The 
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order of permeability ratio (%) of samples from highest to lowest was P188-coated NPs (147 
nm), P80-coated NPs (149 nm), PLGA-PEG-PLGA (PEP) NPs (152 nm), PLGA NPs (173 nm) 
and loperamide in solution. In vitro cytotoxicity studies of all nanoparticles at the loperamide 
concentrations of 5, 10, 15 and 30 ng/ml showed no toxicity. Male ICR mice were used for the in 
vivo antinociception studies of nanoparticles incorporated with loperamide after i.v. 
administration at the dose of 5 mg/kg. Hot-plate test and formalin tests were employed, and the 
results showed P188-coated NPs had the best antinociceptive effects. Distribution of 
nanoparticles with entrapped courmarin-6 in the brain was further studied with male SD rats after 
administration through the tail vein at a dose of 0.5 mg/kg. Quantitative study demonstrated 
P188-coated NPs (200 nm) have the highest concentration in the brain followed by P80-coated 
NPs (190 nm), PEP NPs (196 nm) and PLGA NPs (224 nm). The result was similar to other 
reported study which claimed P188 showed better brain targeting delivery than P80 after surface 
coating on nanoparticles (Kreuter and Gelperina 2008; Kulkarni and Feng 2011). P188-coated 
PEP NPs showed the greatest cellular uptake, brain distribution and best antinociceptive effects 
over P80-coated NPs (Chen, Hsieh et al. 2011). 
Xie et al. (2010):  
To improve brain delivery of paclitaxel, PEG, TPGS, F127 and P80 were used as 
additives or for surface coatings during preparation of nanoparticles of around 200 nm via 
nanoprecipitation. Cellular uptake of all kinds of nanoparticulate formulations loaded with 
coumarin-6 were investigated with MDCK cell monolayer at a dose of 250 μg/ml 2h after 
incubation. Compared to uncoated PLGA NPs, NPs with additives showed enhanced cellular 
uptake, and NPs with the additives of P80 and TPGS demonstrated greatest cellular uptake. 
Surface-coated NPs were proved to be less effective in cellular uptake than those with additives. 
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Cytotoxicity of paclitaxel loaded nanoparticles (paclitaxel 30μg/well) was studied in C6 glioma 
cell line after 3-4 h incubation. The transendothelial electrical resistance (TEER) and cell 
viability were determined to evaluate paclitaxel delivery. Both results showed that NPs with 
TPGS and P80 as additives enhanced paclitaxel greater than other nanoparticulate formulations 
(Xie, Lei et al. 2010). 
Ren et al. (2009):  
Polysorbate 80 (Tween® 80, T80) was coated on the surface of PLA-b-PEG NPs loaded 
with Amphotericin B (AmB) to enhance brain delivery. The effect of different solvent and 
surfactant on size and entrapment efficiency of the drug in the NPs was studied. T80 coated NPs 
with DMSO as solvent (120 nm) achieved highest entrapment efficiency (50.7%). The in vivo 
study performed on Cryptococcal Meningitis-bearing mice after intravenous administration of 
designed NPs (6 mg/kg) showed brain delivery was greatly enhanced as the level of AmB in 
brain increased when compared to that observed with AmB injectable powder (1 mg/kg). Further 
recovery of fungus (Cryptococcal Meningitis) from brain also proved the result. The survival 
time of mice treated with NPs was twice longer than that of the AmB treated group. The toxicity 
of AmB to tissues including liver, kidney and blood system was measured and it was found that 
the accumulation of AmB in liver, spleen and kidney decreased significantly in the NP treated 
animals compared to that of AmB powder treated groups. AmB conjugated PLA-b-PEG NPs 
provided a brain targeting delivery with reduced toxicity of AmB and improved therapeutic 
efficiency (Ren, Xu et al. 2009). 
Wang et al. (2010):  
Trimethylated chitosan (TMC) conjugated PLGA nanoparticles were constructed for the 
delivery of coenzyme Q10 to the brain. Instead of using poly (vinyl alcohol) (PVA), vitamin E 
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succinated polyethylene glycol 1000 (vitamin E TPGS) was successfully used in the preparation 
of Co-Q10 loaded PLGA nanoparticles (147 nm). The conjugation of TMC was confirmed as zeta 
potential increased from -18.3 mV to 21.0 mV. Cytotoxicity was evaluated by MTT assay with 
SH-SY5Y cells; no significant cytotoxic effect of TMC conjugated PLGA NPs was found. The 
AD animal model, transgenic mice characterized by overexpression of Aβ and plaque 
accumulation was used. The biodistribution was investigated by fluorescent microscopy of brain 
sections after caudal vein injection of TMC-conjugated PLGA NPs loaded with coumarin-6 
(136nm). A higher accumulation was observed in the brain parenchyma of the animals treated 
with TMC-conjugated PLGA NPs in comparison to the unconjugated PLGA NPs. According to 
the behavior studies, the memory impairment was greatly attenuated by the TMC-NPs loaded 
with Co-Q10, while unconjugated PLGA –NP did not show any significant improvement over the 
control group. Senile plaque staining showed that senile plaques were reduced after the treatment 
of Co-Q10 loaded TMC-NPs. Behavior, senile and biochemical parameter tests of coenzyme Q10 
loaded TMC-conjugated PLGA NPs (147nm) further confirmed the brain-targeted property and 
superior advantages of TMC/PLGA NPs over uncoated PLGA NPs. Biochemical parameters 
including oxidative stress, malondialdehyde (MDA), GSH-peroxydase (GSH-Px) and catalase 
(CAT) were determined. The MDA level in the brain decreased greatly in TMC-NPs treated 
groups compared to control and PLGA-NPs treated mice (P<0.05). The GSH-Px level and CAT 
level in the brain didn’t show a difference from the control and unmodified NPs treated group, 
and the GSH-Px level and CAT level in TMC-NPs treated mice increased compared to PLGA-





Jalali et al. (2011):  
Vitamin E polyethylene glycol 1000 succinate (vitamin E TPGS) was confirmed to be a 
better emulsifier than PVA by testing the in vitro cytotoxicity of the TPGS-coated PLGA 
nanoparticle tested in PC12 cells. Four concentrations of TPGS (0.02%, 0.06%, 0.12%, and 
0.18%) were used for the preparation of TPGS-NPs (100-400 nm). The effects of different 
emulsifiers (TPGS, PVA, and mixture of both), stirring times on particle sizes, surface 
morphology and phase composition were investigated. In vitro cytotoxicity studies of TPGS-NPs 
in a PC12 cell line, a neural cell model, showed no obvious cytotoxicity. The more TPGS on the 
surface, the more effective therapeutic effects the TPGS-PLGA NPs showed (Jalali, 
Moztarzadeh et al. 2011). 
Jaruszewski et al. (2012):  
The accumulation of amyloid β (Aβ) proteins in the cerebral vasculature causes cerebral 
amyloid angiopathy (CAA) in patients suffering from Alzheimer’s disease. A novel PLGA 
immuno-nanovehicle (265 nm) was designed by coating PLGA with chitosan to enhance stability 
and conjugating with an anti-Aβ antibody to the particles, for the treatment of Alzheimer’s 
disease. Chitosan coated PLGA NP showed cubed-shaped NPs under scanning electron 
microscope (SEM), and the amount of chitosan adsorbed on the surface was 3.09 μg/mg NPs. 
The stability ratio was determined to evaluate the stability of NPs, and the immuno-nanoparticles 
showed the highest stabilities, followed by chitosan coated PLGA NPs and PLGA NPs. To 
evaluate the cellular uptake, polarized MDCK cell monolayer, a commonly used in vitro BBB 
model was used. With coumarin-6 as fluorescent marker, cellular internalization of immuno-
nanoparticles was confirmed by the fluorescence images, which displayed higher fluorescence in 
modified chitosan-PLGA NPs than unmodified chitosan-PLGA NPs. After incubated with Aβ 
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proteins, immuno-nanoparticles demonstrated increased cellular uptake in the MDCK cell 
monolayer. The immuno-nanovehicles were transcytosed across the monolayer which 
demonstrated their ability to potentially cross the BBB (Jaruszewski, Ramakrishnan et al. 2012). 
Parikh et al. (2010):  
The effect of surface charge on brain delivery of sulpiride using surface modified 
pegylated nanoparticles was studied. Alexa Fluor 488 labeled thiolated cationized bovine serum 
albumin (CBSA) (329 nm, -19 mV) and bovine serum albumin (BSA) (308 nm) were conjugated 
to PEG-PLGA nanoparticles which were loaded with Sulpiride and Rhodamine-B. After 
administered to Sprague Dawley rats via tail vein, blood samples (0.5 mL) at 0.5, 1, 2, 4, 8, 16 
and 24 h and total urine accumulated in 24 h were collected. Much less Sulpiride was released in 
plasma from CBSA-NPs in first 5 h compared to BSA-NPs and unconjugated NPs. The low drug 
level of urinary excretion for different formulations (19.26%) confirmed the possibility of 
particles being distributed in the body rather than being cleared. The fluorescent study showed 
that CBSA-NPs were cleared faster from plasma and reached the brain in higher concentrations 
compared to unconjugated NPs (218nm) and BSA NPs. The high uptake in the brain of CBSA-
NPs compared to BSA-NPs proved that positive charge of the CBSA-NPs was the reason of 
higher brain uptake. Most endothelial cells of the BBB are negatively charged, and thus 
positively charged NPs could adsorb on cell surface and be taken up by adsorptive-mediated 
transcytosis (Parikh, Bommana et al. 2010).  
Lu et al. (2007):  
Lu, W.’s group investigated brain delivery of cationic bovine serum albumin (CBSA) 
conjugated PEG-PLA nanoparticles (CBSA-NP). In order to conjugate different concentrations 
of CBSA on the surface of NPs, different weight ratio of Mal-PEG-PLA to MPEG-PLA (1:20, 
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1:10 and 1:5) were used to form NPs measuring in average 105 nm. The BSA-NP was prepared 
with the ratio 1:10 and measured 97.4 nm. The brain transcytosis of CBSA-NP across the 
coculture of endothelial cells and astrocytes was confirmed using coumarin-6 as fluorescent 
probe after incubation for 5, 10, 20, 30 and 60 min. The permeability (Pe) of CBSA-NP was 
higher than that of unconjugated NP, and Pe values increased as the increasing amount of CBSA 
on the surface of NPs. Pre-incubation with 100 µg/ml free CBSA significantly decreased the Pe 
values of CBSA-NP to only 10%. Adsorptive mediated transcytosis (ATM) was believed to be 
the principle brain delivery pathway of CBSA-NP. A dose of 30 mg/kg of the three types of 
CBSA-NP, BSA-NP and unmodified NP with entrapped coumarin-6 as fluorescence probe were 
injected via tail vein in male BALB/c mice. Brain delivery of CBSA-NPs in mice was proved, 
and the optimal brain targeting nanoparticle was determined. The NPs with 110 CBSA/particle, 
with the maleimide-PEG-PLA/methoxy-PEG-PLA weight ratio 1:10 (105 nm) achieved 2.3-fold 
increasing of the percentage of injected dose per gram of brain (%/ID/g brain), compared with 
unmodified NP (Lu, Wan et al. 2007). In their previous study, the effect of particle size on 
transport of methotrexate across the BBB using polysorbate 80-coated polybutylcyanoacrylate 
nanoparticles (PBCA) was investigated, and an average size of 70 nm showed the highest 
accumulation of drug concentration for four different sizes of PBCA nanoparticles (Gao and 
Jiang 2006). The efficiency of brain delivery was lower with the co-injection of free CBSA with 
CBSA-NP compared to those without co-injection. CBSA-NPs were found to distribute more in 
liver and spleen than other organs, and NP clearance by liver and spleen increased with the 
increasing of CBSA content of NPs. Moreover, “accelerated blood clearance (ABC) 
phenomenon” was observed among single dose or over successive high doses of CBSA-NP 
treated profile via blood clearance testing. PEG-PLA NPs also showed an ability to induce the 
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ABC phenomenon in an inversely dose-dependent manner after one-dose treatment. 
Immunoglobulin binding to NP or CBSA-NP was determined via Western blotting analysis. It 
was observed that IgM was induced by both NP and CBSA-NP at day 10 after a dose of 0.005 
mg/kg injection. For the successive treatment study, IgM and specific IgG were only induced by 
CBSA-NP (1:10) at day 10 after 5 successive injection at dose of 180 mg/kg/day. Mild acute 
inflammation of mice cerebrum, liver, spleen and kidney of intravenously injected CBSA-NP 
(1:10) at high dose (180 mg/kg/day) over 7 successive days was detected, it was concluded that 
potential toxicity of ABC phenomenon should be taken into consideration (Lu, Wan et al. 2007).  
Costantino et al. (2005):  
Costantino, L. et al. conjugated five short peptides to PLGA respectively to form peptide-
derivatized PLGA nanoparticles (162-211 nm) with poloxamer 188 (Pluronic® F68) as a 
emulsifier. Fluorescein or tetramethylrhodamine fluorescent probes were covalently linked to 
PLGA polymers, and fluorescent labeled polymers were used to prepare NPs. The ability of 
different nanoparticles to cross the BBB was investigated by the in vivo Rat Brain Perfusion 
Technique. A suspension of NPs (5 mg/mL saline per animal weighting 250 g) was perfused in 
rats in 20 s, and brain was collected after the rat was sacrificed. Fluorescent and confocal 
microscopy studies of brain showed four out of five peptide conjugated nanoparticles were able 
to penetrate the BBB into cerebral parenchyma while unconjugated PLGA nanoparticles were 
not. Moreover, one peptide (H2N-Gly-L-Phe-D-Thr-Gly-L-Phe-L-Leu-L-Ser-O-β-D-glucose-
CONH2) conjugated NPs showed the highest distribution in the brain with the perfusion 





Li et al. (2011):  
A phage-displayed peptide conjugated PEG-PLGA nanoparticles for brain targeting 
delivery was constructed. The 12-amino-acid-peptide (Pep TGN), a non-reported brain-target 
motif, was selected by 4 rounds of in vivo phage display screening with adult male ICR mice. 
Mice were injected in the tail vein with 10
11
 plaque forming units (pfu) of Ph.D.-12
TM
 Phage 
Display Library in 100 μl Tris-buffered saline (TBS). The brain tissue was collected and 
homogenized 24 h after administration, then mixed with E. coli. After the final round of 
biopanning, a total of 20 peptides were screened, and a consensus sequence (TGN) was found in 
60% of peptides via a multiple sequence-alignment analysis using Laser gene program. Both the 
competitive inhibitions and immunohistochemistry studies proved Pep TGN could be a 
promising ligand targeting the brain. Pep TGN was conjugated to PEG-PLGA NPs at 1:3 and 1:1 
ratio to form 115.2 nm and 121.5 nm NPs respectively. In vitro cytotoxicity studies of NP, TGN-
NP (1:3) and TGN-NP (1:1) with bEnd.3 cells after 4 h and 24 h incubation at 37 ℃ revealed 
low cytotoxicity. TGN-PLGA NP proved significant higher bEnd.3 cells uptake in vitro. After 1 
h injection of treatment, enhanced brain targeting delivery of TGN-NPs in vivo was observed 
when compared to empty PLGA nanoparticles using coumarin-6 as fluorescence probe. The 
TGN-NPs with high concentration of TGN on the surface (1:1) displayed higher accumulation in 
the brain than TGN-NPs (1:3). The brain uptake of TGN-NP (1:3) and TGN-NP (1:1) was 55.2 
ng/g and 95.1 ng/g at 1 h, about 2.1 and 3.6 times higher than that of unmodified NPs (26.3 ng/g). 
After 24 h, the brain uptake of TGN-NP (1:3) and TGN-NP (1:1) proved to be 2 and 4-fold 
higher than that of unconjugated NPs. The more TGN was conjugated on the surface, the higher 




Rao et al. (2008):  
Protease inhibitors (PIs), used in the treatment of HIV are mostly known substrates of P-
glycoprotein (P-gp), which hinders the transport across the BBB. Trans-activating transcriptor 
(TAT) peptide conjugated PLA nanoparticles (340 nm) were constructed to provide CNS 
delivery of ritonavir, an anti-HIV drug, to bypass the efflux action of P-gp. The amount of TAT 
peptide attached to the PLA NPs was 0.23 μg/mg NPs, corresponding to about 2012 peptide 
molecules per NP. Madine Darby canine kidney cells over-expressing P-gp (MDCK-MDR1) and 
wild type MDCK (MDCK-wt) were used to evaluate whether ritonavir loaded TAT-NPs 
bypassed the efflux action of P-gp with coumarin-6 as fluorescent marker. Permeability 
coefficient (Papp) was calculated after incubation for 5 h at 37 ℃. Approximately 40-fold 
increased uptake of ritonavir in MDCK-MDR1 using TAT-conjugated PLA nanoparticles (Papp, 
2.4×10
-5
, cm/s) than free ritonavir (Papp, 0.05×10
-5
, cm/s) in solution was proved. TAT-NPs 
showed four-fold greater uptake of ritonavir in MDCK-MDR1 than in MDCK-wt cell lines while 
the uptake of free ritonavir was greater in MDCK-wt than in MDCK-MDR1. The brain drug 
level after intravenous administration of TAT-conjugated nanoparticles (80.3 μg/g of tissue) was 
800-fold higher than that of drug in solution (0.1μg/g of tissue), and 7-fold higher than 
unconjugated NPs (12.2μg/g of tissue) at two weeks. TAT-NPs and unconjugated NPs were 
found to distribute in the brain, heart, spleen and kidney 1 day after administration, and greater 
amounts were found in the spleen than in other tissues. The drug level was sustained in heart and 
spleen from TAT-NPs treated groups for a longer period of time before drug clearance (4 weeks). 
The fluorescent microscopic analysis of brains and further histological analysis of TAT-
conjugated nanoparticles showed that NPs first entered the brain vasculature, and then localized 
in the brain parenchyma without disrupting the BBB integrity (Rao, Reddy et al. 2008). 
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Tosi et al. (2010):  
Sialic acid (SA) and similopioid peptide (g7) conjugated PLGA nanoparticles loaded 
with loperamide (LOP-SA-g7-NP) and a fluorescent dye, Rhodamine-123 (ROD), (ROD-SA-g7-
NP), and labeled with tetramethylrhodamine (TMR-SA-g7-NP) made with poloxamer 188 
(Pluronic® F68) as an emulsifier were synthesized to evaluate central nervous system targeting 
and distribution. LOP-SA-g7-NP (180 nm) was found to reach the brain 15 min after the 
administration and 30%-35% maximal possible effect (MPE) was reached as detected by the 
sudden opioid effect with the antinociceptive testing. The MPE values decreased to 20% after 
30-60 min, increased to 50% after 6 h, and maintained at 30-50% for 15 h. After 24 h, the 
antinociceptive effect of NPs gradually decreased to 10-20% MPE. Compared to their previous 
studies, the effect of LOP-g7-NP was 57% MPE and lasted only 5 h after administration, the 
long-lasting effect of SA-LOP-g7-NP. Higher dose of drug delivered to the CNS provided higher 
MPE values. In vivo fluorescence studies of TRM-SA-g7-NP (154 nm) after intravenous 
administration at 0.5, 1, 2, and 6 h showed TMR-SA-g7-NP distributed in the cerebral 
parenchyma. The 3D confocal images further proved TMR-SA-g7-NP located close to the 
cerebral nuclei of brain cells, and some into the cytoplasm. The retention time of TMR-SA-g7-
NP in the brain was studied by sacrificing rats 15 days, 1, or 2 months after administration. The 
TMR-SA-g7-NP could be detected in the CNS parenchyma after 15 days, but not any more after 
1 month. The in vivo biodistribution studies with ROD-SA-g7-NP (197 nm) showed 4-6% of the 
injected TMR-SA-g7-NP was found into the CNS after 1 h, and it was maintained at this level 
for 6 h, then it decreased to 2% over 24 h. Compared to ROD-g7-NP (169 nm) which showed 
higher amount (13%) at 1.5 h, but decreased faster to 0.7% for 24 h, TMR-SA-g7-NP was 
proved to prolong retention time in brain. However, biodistribution in vivo also showed that 
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ROD-SA-g7-NP were greater accumulated in liver (10-20%), kidney (15-40%) and especially in 
lung (70% -30%) in the first five hours after administration compared to ROD-g7-NP and empty 
PLGA-NP, as SA coverage interacted with specific receptors for SA residues in other organs. 
This result explained the less accumulation of ROD-SA-g7-NP (6%) over ROD-g7-NP (13%) 
over 1 h in the brain (Tosi, Vergoni et al. 2010).   
Mathew et al. (2012):  
A targeting ligand Tet-1 peptide was conjugated to PLGA nanoparticles (150-200nm) to 
improve curcumin delivery to the brain. Curcumin incorporated in PLGA NPs was proved to 
conserve its anti-oxidant and anti-amyloid activity. Cytotoxicity studies of Tet-1 conjugated or 
unconjugated NPs were carried out with LAG cell line (mouse fibroblast like connective tissue) 
using Alamar Blue and MTT assays. No significant cytotoxic effects in vitro of both 
nanoformations were found according to the results. GI-1 glioma cells were used for the cellular 
uptake studies of Tet-1 grafted and unmodified NPs in vitro. Tet-1 conjugated PLGA NPs 
showed multiple folds increased uptake than the unconjugated NPs. Confocal laser scanning 
microscopy studies showed that Tet-1 targeted NPs distributed more around the cell soma and 
nucleus compared to unconjugated NPs. PLGA conjugated with Tet-1 peptide was proved to be a 
potential therapeutic carrier of curcumin for AD treatment (Mathew, Fukuda et al. 2012). 
Geldenhuys et al. (2011):  
Glutathione conjugated PEG-PLGA nanoparticles loaded with paclitaxel (200 nm) were 
constructed to enhance brain-targeted delivery. The effect of glutathione at different 
concentrations (1, 2 and 3% w/v) on average diameter of NPs was investigated first. Particle size 
of NPs decreased with increasing concentration of glutathione used for the synthesis. The 
concentration of 2% w/v glutathione was selected based on the size (237 nm) and PDI (0.74). 
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Intracellular uptake of glutathione modified PLGA-PEG NPs were investigated in RG2 cells, a 
rat glioma cell line, by using a coumarin-6 as fluorescent marker. Enhanced cellular uptake of 
glutathione-conjugated NPs was observed compared to uncoated NPs after incubation for 24 h. 
The cytotoxic efficacy of paclitaxel loaded glutathione-conjugated PLGA-PEG NPs were 
evaluated using MTT assay; higher cytotoxicity was proved for coated NPs compared with 
uncoated NP and free paclitaxel. As tubulin accumulation is induced by Paclitaxel, the 
immunofluorescence of tublin was performed using RG2 cells. Glutathione conjugated PLGA-
PEG NPs showed higher accumulation of acetylated tubulin than uncoated NP and control. 
When compared to 1% Tween coated NPs, the cytotoxic effect and tubulin levels of 2% 
glutathione coated NPs were similar. Western blotting analysis further confirmed this result. In 
vivo brain uptake and biodistribution studies in brain tumor mouse model after 0.2 mL of 5 
mg/kg NPs intraperitoneally administration, enhanced brain uptake compared with uncoated NPs 
was evidenced as well (Geldenhuys, Mbimba et al. 2011). 
Chang et al. (2009):  
The brain uptake mechanisms of transferrin (TF) conjugated PLGA NP with Dil as a 
fluorescent marker was studied. Fluorescent labeled Tween 20 and BSA coated PLGA NPs, and 
unmodified PLGA NPs were prepared as controls. Unmodified NPs without Tween 20 coalesced 
quickly, thus proteins were conjugated on the PLGA NPs to maintain NPs stable for at least 12 
days at 37 ℃. The amount of Tf and BSA conjugated to the NPs was 89μg and 126 μg per mg 
NPs. Cytotoxicity studies on the integrity of BBB using either Lucifer Yellow or sucrose 
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revealed high toxicity of Tween 20 coated PLGA NPs, and thus Tween 20 coated PLGA NPs 
were discarded in the following studies. An in vitro model of a co-culture of brain endothelial 
cells (BCECS) and astrocytes (glial cells) which mimic the BBB was prepared for the cellular 
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uptake study. Compared to unconjugated PLGA nanoparticles (63 nm) and BSA-coated PLGA 
nanoparticles (89 nm), uptake of Tf-coated PLGA nanoparticles (90 nm) was found 20-fold and 
2-fold respectively greater after 1 h incubation. Endocytosis using an energy-dependent process 
was confirmed as the endocytosis of NPs was inhibited by low temperature and the presence of 
sodium azide and excess free Tf in solution. Inhibitors studies were carried out to investigate the 
mechanism of endocytosis. After incubated with filipin, a caveolae inhibitor, Tf-NPs showed 
significantly decreased cellular uptake compared to unconjugated NPs and BSA-NPs, which 
suggested a specific caveolae-mediated transcytosis of Tf-NPs and a adsorptive mediated 
endocytosis of unmodified NPs and BSA-conjugated NPs (Chang, Jallouli et al. 2009). 
Gan and Feng (2010):  
Transferring (Tf) conjugated nanoparticles of Poly (lactide)-D-α-Tocopheryl 
polyethylene glycol succinate diblock copolymer (PLA-TPGS) with entrapped docetaxel 
(Taxtere®) (137.6 nm) was prepared. Cellular uptake and cytotoxicity of the Tf-conjugated 
PLA-TPGS NPs with entrapped coumarin 6 as a fluorescent marker were evaluated and 
compared to unconjugated PLGA NPs in C6 glioma cell line for 4 h. The Tf conjugated PLA-
TPGS NPs showed the highest cellular uptake, followed by unconjugated PLA-TPGS NPs and 
PLGA NPs. Following pre-incubation with an excess of Tf for 1 h, the cellular uptake of Tf-
PLA-TPGS NPs decreased and was similar to that of the unconjugated PLA-TPGS NPs, which 
suggested that a receptor-mediated endocytosis process was involved. In vivo biodistribution of 
Tf-conjugated PLA-TPGS NPs was compared with that of PLGA NPs, PLA-TPGS NPs and 
docetaxel 24 h after intravenous injection in rats. Tf-conjugated PLA-TPGS NPs was proved to 
be able to cross the BBB, and showed a much higher concentration compared to unconjugated 
PLA-TPGS NPs. In vitro cytotoxicity of docetaxel loaded PLA-TPGS NPs with or without Tf 
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modification was evaluated with C6 glioma cells after incubation at 37 ℃ after 24 h, 48 h and 72 
h. Tf conjugated PLA-TPGS NPs proved the lowest cytotoxicity compared with unconjugated 
PLA-TPGS, PLGA NPs and solution docetaxel. Furthermore, IC50, a quantitative index of 
inhibitory concentration was employed to demonstrate the advantages of the Tf-conjugated PLA-
TPGS NPs. Based on the IC50 data of the designed NPs loaded with docetaxel, it was concluded 
that Tf-conjugated PLA-TPGS NPs could be 23.4%, 16.9% and 229% more efficient than 
unconjugated PLGA NPs, PLA-TPGS NPs and docetaxel respectively (Gan and Feng 2010).  
Jain et al. (2011):  
Transferrin (Tf) was conjugated on the surface of PEG-PLGA NPs (121 nm) to improve 
temozolomide delivery to brain. In vitro cytotoxicity studies of Tf-PEG-PLGA NPs with 
incorporated temozolomide were investigated with eight human cancer cell lines of six different 
human cancer tissues including prostate, colon, breast, neuroblastoma, CNS and lungs after 
incubation for 48 h. Cells exposed to PEG-PLGA NPs and Tf-PEG-PLGA NPs showed the 
lowest cell viability compared to those exposed to PLGA NPs. Confocal laser scanning 
microscopy (CLSM) of brain 4h after i.v. administration of all formations of nanoparticles 
showed PEG-PLGA NPs and Tf-PEG-PLGA NPs distributed in the brain, and Tf-PEG-PLGA 
NPs were found within the brain parenchyma. All these results demonstrated Tf conjugated 
PEG-PLGA NPs improved brain delivery of temozolomide (Jain, Chasoo et al. 2011). 
Kuo et al. (2011):  
Transferrin (Tf) grafted PLGA NPs (170-200nm) were synthesized with 
dioctadecyldimethylammonium bromide (DODAB) as emulsifier to enhance nevirapine (NVP) 
delivery across human brain microvascular endothelial cells (HBMECs). The effects of Tf and 
DODAB on cell viability of HBMECs at a dose of 0.0125% (w/v) NVP loaded Tf-PLGA NPs 
39 
 
were investigated. An increase of DODAB concentration (33%-100%) in Tf-NPs reduced the 
cell viability of HBMECs to 70-75%. Tolerable toxicity and mild secretion of TNF-α were 
observed. Permeability studies of NVP loaded Tf-PLGA NPs with the concentration of 0.05 
mg/ml revealed nanoparticles with 67% DODAB reached the highest permeability followed by 
100% and 0% DODAB emulsified NPs. The uptake of fluorescent Tf-PLGA NPs loaded with 
NVP was 3.2 times greater than unmodified NPs. According to all results, the optimum condition 
for NVP delivery with Tf-PLGA NPs for this study was 67% DODAB, 0.05% NVP and 0.1% Tf 
(Kuo, Lin et al. 2011). 
Carroll et al. (2010):  
A transferring antibody (OX 26) was covalently linked to PLGA-PEG NPs (105 nm) to 
enhance brain delivery of entrapped Tempol. P-gp-ATP assay was employed to study the ability 
of the NPs to prevent P-gp efflux. Incubated NPs with P-gp didn’t show any increase in ATPase 
use, which indicated the OX 26 conjugated NPs were not the substrate for P-gp. An enhanced 
cellular uptake of conjugated NPs was observed compared to unconjugated NPs in RG2 rat 
glioma cells using coumarin 6 as a fluorescence label. Cell proliferation study via MTT assay 
proved conjugated PLGA NPs were more efficient in preventing cell viability than unconjugated 
NPs and free Tempol in RG2 rat glioma cells after incubation for 24 h at 37 ℃ (Carroll, Bhatia 
et al. 2010). 
Grabrucker et al. (2011):  
Grabrucker A.M. el al developed glycopeptides-conjugated PLGA NPs (BBB-NPs) for 
Zn
2+
 (190-210 nm) delivery to CNS. Cytotoxicity studies of unloaded or Zn
2+ 
loaded PLGA NPs 
and BBB-NPs were carried out with neuronal/glial cultures. Unloaded PLGA NPs and BBB-NPs 
showed no significant toxic effects on cells at a concentration of 625 µg/ml, and double or triple 
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this concentration. However, a significant reduction of cell viability was observed at 8× (BBB-
NPs) and 10× (both NPs). Uptake studies revealed that BBB-NPs improved endocytosis 
compared to unconjugated NPs with tetramethylrhodamine covalently linked with NPs. To 
achieve selective targeting to neurons (NCAM1 labeled) or glial cells (CD44 labeled), anti-
NCAM1 antibody and anti-CD44 antibody were conjugated on the surface of nanoparticles, 
respectively. Specific targeting of antibody modified NPs was observed (Grabrucker, Garner et 
al. 2011). 
Hu et al. (2011):  
Lactoferrin (Lf) conjugated PEG-PLGA nanoparticles (Lf NP) entrapped with urocortin 
(UCN) were synthesized and both in vitro and in vivo targeting delivery was evaluated. 
Coumarin-6 incorporated in the NPs (120nm) was used as a fluorescence probe. In vitro cellular 
uptake was carried out in bEnd.3 cells, a model of the BBB, after incubation with coumarin-6 
loaded Lf-NPs and unconjugated NPs for 0.25, 0.5 and 1 h at 37 ℃. A time-, temperature-, and 
concentration-dependent cellular uptake was confirmed. About 3.9-fold higher cellular uptake of 
Lf-NP was observed over unconjugated NPs at 4 h. Excess free Lf was added to evaluate the 
inhibitory effect of Lf on Lf-NPs uptake. The efficiency of Lf-NPs in the presence of excess Lf 
decreased to 30% of the efficiency of NPs without free Lf. Further inhibitory studies with 
chlorpromazine which inhibits clathrin-dependent process and filipin which inhibit caveolae-
dependent process were carried out. The uptake method of Lf NP was proved to be an additional 
clathrin-mediated endocytosis processes induced by Lf. After intravenous administration in 6-
OHDA rat model of Parkinson’s disease, Lf-NPs accumulated more in heart and spleen but less 
in kidney compared to unmodified NPs. Moreover, Lf-NP showed 2.49-fold of coumarin-6 
accumulation in the brain of rats than unconjugated NP in 24 h, and mainly distributed in the 
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cortex, substantia nigra and striatum region. Urocortin (UCN) was entrapped in the Lf-NPs to 
study the therapeutic effect on 6-OHDA rat model of Parkinson’s disease. The behavior test was 
carried out at 7, 14 and 21 days after the rats were injected with UCN loaded Lf-NPs and 
unconjugated NPs. Immunohistochemistry stain of tyrosine hydroxylase and striatal transmitter 
contents were also used to evaluate the therapeutic effects of the NPs. The rotation behavior of 6-
OHDA was greatly attenuated by UCN loaded LF-NPs after intravenous administration. The 
TH-immunoreactivity was significantly improved after LF-NP with entrapped UCN compared to 
other treatment groups. The percentage of DA in the striatum was significantly increased after 
Lf-NPs injection at 21 days. Lf-NP showed relatively low toxicity via in vitro cell viability 
experiment. In vivo CD 68 immunohistochemistry, which was used to investigate the acute 
inflammation of NPs showed dose-dependent inflammatory reactions in liver, spleen and kidney 
at 24 h which disappeared at 48 h after successive administration of LF-NP for 7 days, but no 
obvious inflammatory reactions to other tissues. The results proved Lf NPs was a promising 
brain delivery carrier for drug with low toxicity (Hu, Shi et al. 2011).  
Kuo and Yu (2011):  
Biodegradable poly-(γ-glutamic acid) (γ-PGA), a natto mucilage from certain strains of 
Bacillus subtilis was used to enhance cellular internalization. In this study, γ-PGA was grafted to 
the surface of PLGA nanoparticles to enhance the transport of saquinavir (SQV) across the BBB. 
Three kinds of γ-PGA of three molecular weight: 6, 14 and 52 kDa measuring 188.8, 218.1, and 
307.6 nm respectively were used for the preparation of γ-PGA PLGA NPs with didecyl 
dimethylammonium bromide (DDAB) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[carboxy(polyethylene glycol)-2000] (DSPE-PEG(2000)-carboxylic acid) as stabilizer. The 
effect of percentage of DDAB used for the synthesis on the average particles diameter of γ-PGA 
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conjugated PLGA NPs was studied as well. An increase in the concentration of DDAB (0.02, 
0.04, and 0.06%) increased the average size of NPs and the conjugation efficiency due to 
electrostatic interaction. The permeability of γ-PGA NPs with entrapped SQV was studied in the 
co-cultured Human brain-microvascular endothelial cells (HBMEC)/human astrocyte (HA) 
system. The effects of different molecular weights and grafting efficiency of γ-PGA to the 
permeability of SQV across a monolayer of human brain-microvascular endothelial cells 
(HBMECs) were investigated, and proved that the maximal permeability was achieved by the 
6kDa of γ-PGA conjugated PLGA NPs (85.2% grafting efficiency, 180 nm) which was 6 times 
enhanced over that of free SQV. The abilities of γ-PGA to promote the endocytosis of NPs and 
expression of ornithine decarboxylase (ODC) by HBMECs, which could enhance the delivery to 
the CNS, were also demonstrated. An increase of γ-PGA on the surface of NPs enhanced the 
uptake of γ-PGA conjugated NPs (Kuo and Yu 2011). 
Guo et al. (2011):  
AS1411 (Ap), a DNA aptamer was conjugated to the PEG-PLGA nanoparticles (156 nm) 
to enhance the brain delivery of paclitaxel (PTX, Taxol®) for the treatment of glioma. The 
conjugation of Ap to NP was confirmed using Urea polyacrylamide gel electrophoresis (PAGE) 
and X-ray photoelectron spectroscopy. In vitro PTX release from Ap-PTX-NP was 43.3% in 
PBS and 46.8% in plasma after 24 h, which was quite similar to that from PTX-NP. 
Fluorescently labeled Ap-NPs were proved to enhance cellular association in C6 glioma cells 
compared to unmodified NPs. Cellular uptake was reduced when incubated with excess Ap. Cell 
viability of C6 cells was evaluated using MTT assay, showing significantly enhanced 
cytotoxicity of PTX when loaded in Ap-NP over free PTX (2.59, 4.18 and 4.67 times) and 
unconjugated PTX loaded NP (2.92, 3.32, and 2.67 times) after incubation for 24 h, 48 h and 96 
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h, respectively. A pharmacokinetic study showed prolonged retention time of NPs after 
intravenous administration at a dose of 3 mg/kg in rats for 0.1, 0.25, 0.5, 0.75, 1, 2, 4, 8, 12 and 
24 h. The highest concentration of PTX in the tissue from Ap-PTX-NP was found in the liver 
compared to those treated with PTX-NP and PTX. Ap-PTX-NP showed the highest efficiency of 
drug delivery to the tumor, which was 1.57-fold over that of PTX-NP and 2.44-fold than that of 
PTX respectively after 24 h. Rats bearing glioma xenograft and intracranial glioma were used to 
investigate biodistribution and anti-glioma efficacy of PTX loaded AP-NP in vivo. After 
intravenous administration of treatment for 20 days, growth, volume, and weight of xenograft 
tumors were characterized. The average tumor inhibition of Ap-PTX-NP, PTX-NP and PTX for 
tumor volume was 81.6, 66.9 and 68.6%, and 79.3, 68.6, and 48.2% for tumor weight. The 
survival times of Wistar rats bearing intracranial C6 glioma  with the treatment of saline, PTX, 
PTX-NP and Ap-PTX-NP were 18, 24, 27 and 31 day respectively. Ap-PTX-NP proved to 
inhibit tumor more effectively and greatly prolonged survival time of the animals (Guo, Gao et al. 
2011).  
2.3. Discussion 
Among 29 papers cited in this review, nine papers performed in vitro studies (Chang, 
Jallouli et al. 2009; Carroll, Bhatia et al. 2010; Xie, Lei et al. 2010; Grabrucker, Garner et al. 
2011; Jalali, Moztarzadeh et al. 2011; Kuo, Lin et al. 2011; Kuo and Yu 2011; Jaruszewski, 
Ramakrishnan et al. 2012; Mathew, Fukuda et al. 2012), 8 papers focused on in vivo studies (Sun, 
Xie et al. 2004; Costantino, Gandolfi et al. 2005; Ren, Xu et al. 2009; Gelperina, Maksimenko et 
al. 2010; Parikh, Bommana et al. 2010; Tosi, Vergoni et al. 2010; Tahara, Miyazaki et al. 2011; 
Tsai, Chien et al. 2011), and 12 papers did both in vitro and in vivo studies (Lu, Wan et al. 2007; 
Rao, Reddy et al. 2008; Gan and Feng 2010; Wang, Wang et al. 2010; Chen, Hsieh et al. 2011; 
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Geldenhuys, Mbimba et al. 2011; Guo, Gao et al. 2011; Hu, Shi et al. 2011; Jain, Chasoo et al. 
2011; Kulkarni and Feng 2011; Li, Peng et al. 2011; Mittal, Carswell et al. 2011). 
2.3.1. In vitro studies 
In vitro studies were usually conducted in brain endothelial cell lines (bovine, human and 
rat), Madin-Darby Canine kidney cells and glioma cells. In vitro studies were performed to 
investigate cytotoxicity, uptake efficiency, endocytosis mechanism and drug efficiency with 
different cell lines. All the aspects are discussed in the following sections. 
2.3.1.1.  Cytotoxicity 
The uptake efficiency, internalization mechanisms, and cytotoxicity of nanoparticles have 
been studied with different cell lines. In addition to naked NPs, PLGA/PLA NPs were coated to 
change the surface property or linked with a targeting ligands to trigger adsorptive-mediated or 
receptor-mediated transcytosis to the CNS (Patel, Zhou et al. 2011). The cytotoxicity studies of 
TMC-TPGS-PLGA NPs (136 nm) with SH-SY5Y cells (Wang, Wang et al. 2010), TPGS-PLGA 
NPs (250 nm) with PC 12 cell line (Jalali, Moztarzadeh et al. 2011), TGN-PEG-PLGA NPs (119 
nm) with bEnd.3 cells (Li, Peng et al. 2011), Tet-1 PLGA NPs (150-200) with LAG cell line 
(mouse fibroblast like connective tissue) (Mathew, Fukuda et al. 2012) and Lf-PEG-PLGA (120 
nm) with bEnd.3 cells (Hu, Shi et al. 2011) demonstrated no significant cytotoxicity of all 
formations of nanoparticles at a dose range of 0.075-8000 μg/ml. 
2.3.1.2.  Uptake efficiency 
Cellular uptake was investigated by fluorescent or confocal microscopy studies, showing 
enhanced internalization of surface modified nanoparticles compared to unmodified 
nanoparticles. Different cells including MDCK cells (Rao, Reddy et al. 2008; Xie, Lei et al. 2010; 
Kulkarni and Feng 2011; Jaruszewski, Ramakrishnan et al. 2012), BCEC cells (Lu, Wan et al. 
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2007; Chang, Jallouli et al. 2009; Chen, Hsieh et al. 2011; Kuo, Lin et al. 2011; Kuo and Yu 
2011), bEnd.3 cells (Hu, Shi et al. 2011; Li, Peng et al. 2011), and glioma cells (Carroll, Bhatia 
et al. 2010; Gan and Feng 2010; Xie, Lei et al. 2010; Guo, Gao et al. 2011) were used as in vitro 
cell models treated at dose ranging from 10 to 15000 μg/ml. Decreasing size, positive charge and 
less hydrophilic NPs were associated with enhanced cellular uptake (Kulkarni and Feng 2011). 
After coating with TMC, a cationic ligand, zeta potential of NPs increased from -18 to 21 mV, 
and the active transport of NPs via AMT was confirmed (Wang, Wang et al. 2010). TPGS and 
surfactants such as T80 and F68 coated NPs have been proven to have an improved cellular 
uptake due to changes of NP surface properties such as surface charge and surface hydrophilicity 
(Kulkarni and Feng 2011). MDCK cellular uptake of TPGS-PLGA NPs (222nm) showed 1.5-
fold higher than PVA-emulsified NPs 4h after incubation (Kulkarni and Feng 2011). The 
permeation percentages of loperamide entrapped F68- and T80-PLGA NPs (21% and 14.5%) 
were significantly increased compared to loperamide loaded PLGA NPs (4.5%) and free 
loperamide (0.4%) (Chen, Hsieh et al. 2011). 
Targeted ligands conjugated on the surface could provide a receptor-mediated 
endocytosis as opposed to non-specific endocytosis. Cellular uptake of Tf-PLGA NPs (90 nm) 
was found 20-fold and 2-fold respectively greater than unmodified PLGA NPs and BSA-PLGA 
NPs (88 nm) 1h after incubation with BCECS. In one study, anti NCAM1 antibody conjugated 
PLGA NPs (190-210 nm) distributed more in neurons labeled with NCAM1 while anti-CD44 
antibody conjugated PLGA NPs (190-210 nm) targeted more glial cells labeled with CD44 
(Grabrucker, Garner et al. 2011).  
The endocytosis process was proven by changing the temperature-, concentration-, and 
time-dependent uptake and co-incubating cells with free targeting ligand and NaN3 which stops 
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energy-dependent processes indicating active endocytosis process (Chang, Jallouli et al. 2009; 
Hu, Shi et al. 2011). Furthermore, the uptake mechanisms of different ligand-conjugated 
nanoparticles were studied with cells pre-incubated with inhibitors. By using chlorpromazine 
which inhibits clathrin-dependent and caveolae-dependent pathway, colchicines which inhibits 
macropinocytosis pathway, and BFA which inhibits Golgi apparatus and lysosome related 
endocytosis process, transport of Lf-TPGS-PLA NPs (120 nm) across the membrane was proved 
to be clathrin mediated endocytosis (Hu, Shi et al. 2011). The mechanism of uptake of Tf-PLGA 
NPs (90 nm) was confirmed as caveoale-dependent by co-incubating cells with filipin, a 
caveolae inhibitor, and other different types of inhibitors. Co-incubated blank NPs with filipin 
did not show inhibition of NP cellular uptake which indicated that endocytosis of blank NPs 
might be adsorptive mediated endocytosis (Chang, Jallouli et al. 2009).  
2.3.1.3.  Therapeutic efficacy 
A number of in vitro experiments have proved that surface functionalized nanoparticles 
enhanced the therapeutic efficacy of antitumor drugs against the glioma cells such as RG2 and 
C6 glioma cells when compared to that of the free drugs in solution and unmodified 
nanoparticles with entrapped drugs (Carroll, Bhatia et al. 2010; Xie, Lei et al. 2010; Geldenhuys, 
Mbimba et al. 2011; Guo, Gao et al. 2011; Kulkarni and Feng 2011; Li, Peng et al. 2011). 
Besides the cell viability, IC50, the concentration of the drug required to kill 50% of the 
incubated cells over a fixed time period, was employed to quantify and evaluate the cytotoxicity 
of NPs loaded with chemotherapeutic drugs, and their therapeutic efficiency. The lowest IC50 
(1.63 μg/ml) for surfactant coated NPs with entrapped docetaxel was achieved with the F68-
PLGA NPs (196 nm) after 24 h in C6 glioma cell lines, which was 94.30% more efficient than 
docetaxel (Kulkarni and Feng 2011). AP-PEG-PLGA with entrapped paclitaxel NPs (156 nm) 
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showed 2-4 times lower IC50 than unmodified NPs and free drug (Guo, Gao et al. 2011). 
Glutathione-coated PEG-PLGA NPs (237 nm) with entrapped paclitaxel showed significantly 
higher therapeutic efficiency than uncoated NPs and paclitaxel solution. Tubulin 
immunofluorescent and western blotting studies also confirmed the enhanced therapeutic 
efficacy of paclitaxel entrapped glutathione-coated NPs (Geldenhuys, Mbimba et al. 2011).  
2.3.2. In vivo studies 
 
In vivo studies were conducted in rats or mice after administration (oral, carotid artery, or 
intravenous) of the nanoparticles. Several experiments including brain uptake quantification, 
confocal laser scanning microscopy, behavior studies, therapeutic efficacy of drugs and in vivo 
toxicity were carried out. The % brain uptake was calculated when the results were not reported 
and expressed as percentage of dose administered per animal, and data was plotted over a 24 hr 
time span (Lu, Wan et al. 2007; Rao, Reddy et al. 2008; Ren, Xu et al. 2009; Gan and Feng 2010; 
Tosi, Vergoni et al. 2010; Hu, Shi et al. 2011; Kulkarni and Feng 2011; Mittal, Carswell et al. 
Figure 2.1 Schematic of three categories of PLGA/PLA NPs. Three types of PLGA/PLA NPs 




2011; Tahara, Miyazaki et al. 2011; Tsai, Chien et al. 2011). In all cases, the brain weights of rat 
and mice used to convert % dose/g reported by some authors to % dose were 2 g and 400 mg, 
respectively (Rosen GD 2000). NP types were divided into three categories: unmodified 
PLGA/PLA NPs, surface-coated NPs, and ligand-conjugated NPs (Figure 2.1). Brain uptake of 
unmodified PLGA/PLA NPs which were the control group in most cases, was important to 
confirm the safety of PLGA/PLA NPs. After synthesis of PLGA/PLA NPs, surfactants such as 
polysorbate 80 and polymers such as TMC could be coated on the surface of NPs to enhance 
brain uptake; this was for the second category “surface coated” NPs. Specific ligands which 
interact with surface receptors on brain endothelial cells could also be covalently linked to NPs 
and thus provide a brain targeted delivery; the third category: targeting ligand conjugated NPs. 
Polyethylene glycol (PEG), a hydrophilic polymer was commonly used to improve brain 
delivery. PEG-containing NPs were proved to have advantages such as stability, prolonged blood 
circulation time, reduced liver distribution and enhanced brain uptake (Chen and Liu 2011). In 
this review, PEGylated NPs PEG-PLGA and PEG-PLA were reported in 10 papers (Lu, Wan et 
al. 2007; Ren, Xu et al. 2009; Carroll, Bhatia et al. 2010; Parikh, Bommana et al. 2010; Chen, 
Hsieh et al. 2011; Geldenhuys, Mbimba et al. 2011; Guo, Gao et al. 2011; Hu, Shi et al. 2011; 
Jain, Chasoo et al. 2011; Li, Peng et al. 2011), and are included in the discussion.                  
2.3.2.1.  Unmodified PLGA/PLA NPs 
Brain uptake of PLGA/PLA nanoparticles (100-300 nm) were tested at different doses, 
ranging between 0.02 to 5.25 mg/animal, by quantifying concentration of entrapped drug (Rao, 
Reddy et al. 2008; Mittal, Carswell et al. 2011; Tsai, Chien et al. 2011) or fluorescent marker  
(Lu, Wan et al. 2007; Gan and Feng 2010; Tosi, Vergoni et al. 2010; Hu, Shi et al. 2011; 
Kulkarni and Feng 2011; Tahara, Miyazaki et al. 2011) after administration to rats (Gan and 
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Feng 2010; Tosi, Vergoni et al. 2010; Kulkarni and Feng 2011; Mittal, Carswell et al. 2011; 
Tahara, Miyazaki et al. 2011; Tsai, Chien et al. 2011) or mice (Lu, Wan et al. 2007; Rao, Reddy 
et al. 2008; Hu, Shi et al. 2011) (Figure 2.2). In all cases, the percentage of dose administered 
that was transported to the CNS was below 4%, and the majority of the studies (7 out of 9 
reported in this review) showed percentages lower than 1%. The highest brain uptake (4%) was 
achieved 1 h after carotid artery administration of PLGA-NPs (200 nm) at a dose of 5 mg with 
coumarin 6 as an entrapped fluorescent marker (Tahara, Miyazaki et al. 2011). Carotid artery 
administration was proven to be more effective than intravenous administration for brain 
delivery as expected, since NPs could be transported directly to the brain after carotid artery 
administration (Tahara, Miyazaki et al. 2011). Oral administered PLGA NPs (134 nm) could 
only reach the brain at a 0.09% of the initial dose 24 h after administration (Mittal, Carswell et al. 
2011). Curcumin-loaded PLGA NPs (163 nm) were found to have the lowest brain uptake (about 
0.02%) according to quantification of drug level in the brain 1 hr after intravenous administration 
(Tsai, Chien et al. 2011). In the cases which measured level of entrapped drug were used to 
determine brain uptake of NPs, brain uptakes of NPs was less than 0.17% (Mittal, Carswell et al. 
2011; Tsai, Chien et al. 2011). However, the study that employed PLA NPs loaded with 
3
H-
ritonavir, a radioactive labeled drug (300 nm) indicated a higher % (0.6-1.7% initial dose) 
reached the brain 24 h post administration (Rao, Reddy et al. 2008). Considering the potential 
degradation of drugs in vivo and the sensitivity of the equipment or method used to measure the 
concentration of drugs, the lower dose of NPs detected in the brain was expected when the 
method of detection was based on entrapped unmodified drug versus radiolabeled drug.  
Three papers claimed there was no evidence showing that unmodified NPs crossed the 
BBB by detecting fluorescence in the brain (Sun, Xie et al. 2004; Costantino, Gandolfi et al. 
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2005; Wang, Wang et al. 2010). Two studies reported low intensity of a fluorescent probe loaded 
in unmodified nanoparticles after administration in the brain (Parikh, Bommana et al. 2010; 
Geldenhuys, Mbimba et al. 2011). In most cases (11 out of 14 papers), unmodified PLGA/PLA 
NPs were found to cross the BBB at a relatively low percentage even after i.v. administration of 
a high NP dose (5 mg/animal). Regardless of the emulsifiers used to prepare nanoparticles, 
different administration methods and quantification methods (drug or fluorescent marker), the 
uptake was always less than 4 % and in most cases lower than 1 %.  
 
Figure 2.2. Percentage (%) unmodifided NPs brain uptake of dose administered versus 
time.The legend information is presented in the following order: NP type, size, emulsifier 
(n/r- not reported), administration (i.v.-intravenous administration; c.a.-carotid artery), 





Table 2.2 Percentage (%) brain uptake of surface coated PLGA/PLA NPs. Size (nm), administration, dose (μg/dose), quantification 




































Abbreviation: Admin.-administration; c.a.-carotid artery; CS-chitosan; EF-entrapped fluorescence marker; F127-poloxamer 407; F68-
poloxamer 188; i.v.-intravenous; N/A-not available; Quant.-quantification method; T80-Tween 80/polysorbate 80; TPGS- D-α-
tocopheryl polyethylene glycol 1000 succinate
  
Percentage brain uptake (%) 
NPs 
Size    
(nm) 
Admin. Dose (μg/ml) Quant. 
Animal 
model 
0.5h 1h 1.5h 3h 6h 12h 24h 
1% T80-PLGA NPs (Mittal, 
Carswell et al. 2011)  
138 Oral 100/200/400 
Drug Rats 
      
0.078/0.052/0.037 
4% T80-PLGA NPs 
 (Mittal, Carswell et al. 2011) 
157 Oral 100/200/400 
      
0.166/0.112/0.088 
1% T80-PLGA NPs   
(Mittal, Carswell et al. 2011) 
138 i.v. 100 
      
0.38 
TPGS-PLGA NPs   
(Kulkarni and Feng 2011) 




    
T80-PLGA NPs  
(Kulkarni and Feng 2011) 
194 i.v. 20 
  
4.3 
    
F127-PGLA NPs  
(Kulkarni and Feng 2011) 
188 i.v. 20 
  
5.5 
    
F68-PLGA NPs  
(Kulkarni and Feng 2011) 
196 i.v. 20 
  
6.2 
    
CS-PLGA NPs  
(Tahara, Miyazaki et al. 2011) 




     
T80-PLGA NPs  
(Tahara, Miyazaki et al. 2011) 
231 c.a. 5000/10000/25000 
 
6.4/6/4.6 
     
F68-PLGA NPs  
(Tahara, Miyazaki et al. 2011) 
252 c.a. 5000/10000/25000 
 
3.2/3.4/1.5 
     
T80-PLA-PEG NPs   
(Ren, Xu et al. 2009) 
120 i.v. 150 Drug Mice 3.52 11.9 
 
13.5 15.7 17.3 11.9 
TPGS-PLGA NPs  
(Gan and Feng 2010) 
121 i.v. N/A EF Rats 
 
1 
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2.3.2.2.  Surface coated nanoparticles 
Brain uptake: 
Besides changing the surfactant used in NP synthesis, the surface of the NP can 
bemodified by the addition of other compounds, such as chitosan or PEG, in an attempt to 
improve brain NP uptake (Table 2). TPGS has been successfully used to prepare NPs, and It was 
found that TPGS was a more effective and safer emulsifier than PVA, and could improve 
adsorption of NPS by the gastrointestinal tract to improve bioavailability of the delivered drug 
(Jalali, Moztarzadeh et al. 2011). TPGS-PLGA NPs demonstrated modest increase of brain 
uptake (1%) 1h after i.v. administration compared to PVA-PLGA NPs (0.5%) (Gan and Feng 
2010). Brain delivery of modified PLGA/PLA NPs was improved when positively charged 
compared to unmodified NPs. The highest brain uptake (16%) was achieved with CS-PLGA NPs 
(396 nm) after carotid artery administration for 1 h (Tahara, Miyazaki et al. 2011). The same 
group demonstrated that although CS-PLGA NPs (396 nm) reached the highest brain uptake, 
NPs were only observed on vascular endothelial cells and considering that CS could open 
intracellular tight juctions, it was concluded that CS-PLGA NPs might not be a good brain 
delivery system (Tahara, Miyazaki et al. 2011). Carotid artery administration was proven to be 
the most efficient for improved brain uptake, followed by intravenous administration, and oral 
delivery (Mittal, Carswell et al. 2011; Tahara, Miyazaki et al. 2011).  
The amount of NPs transported to the brain (μg/g tissue) reported in the literature 
increased as the increase of dose administered while percentage (%) of dose calculated by the 
author did not show a dose-dependent increase. For example, F68-PLGA NPs remaining in the 
brain 60 min after NP administration via carotid artery was 0.08, 0.17 and 0.19 mg/g tissue at 
injected doses of 5, 10 and 25 mg/ml respectively which corresponded to 3.2, 3.4 and 1.5%. 
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Among all the surfactants used to enhance brain delivery, T80 was the most commonly 
used. T80 coating could adsorb apolipoprotein E/B from the blood on the nanoparticle surface 
and thus provided a receptor-mediated active endocytosis of the NPs (Wohlfart, Gelperina et al. 
2011). For i.v. administration of surfactant coated PLGA NPs, F68 was confirmed to be a better 
targeting agent than T80 (Kreuter 2001; Gelperina, Maksimenko et al. 2010). Kulkarni, S.A. and 
S.S. Feng compared the brain uptake of F68, F127 and T80 coated PLGA NPs, and found that 
F68-PLGA NPs (252 nm) reached the highest brain distribution (6.2%) via i.v. injection 
(Kulkarni and Feng 2011). When comparing the anti-tumor effect of drug loaded in T80 and F68 
coated PLGA NPs, Gelperina, S. et al found as well that F68-coated NPs (168 nm) had a higher 
therepeutical efficacy than T80-PLGA NPs after i.v. administration (Gelperina, Maksimenko et 
al. 2010). Kreuter J. and Gelperina S. demonstrated that F68 appeared to be a very promising 
coating agent for both PLGA and PBCA NPs, while T80 was only effective in the case of PBCA 
NPs comparing Kulkarni’s finding (Kreuter and Gelperina 2008). However, c.a. administration 
showed a different delivery trend between T80 and F68 coated NPs: T80-PLGA NPs (231 nm) 
proved to be delivered at a higher percentage (6%) than F68-PLGA NPs (252 nm)(3%) (Tahara, 
Miyazaki et al. 2011). For the same surfactant and same administration, the more surfactant 
coated on the nanoparticle surface, the higher the brain nanoparticles uptake (Mittal, Carswell et 
al. 2011).  
Location of NPs in the brain: 
Fluorescent microscopy studies focused on identifying the location of the NPs in the 
brain  revealed that T80-PLGA NPs with entrapped coumarin-6 (215 nm) and very small amount 
of F68-PLGA NPs (252 nm) distributed in the parenchyma (Tahara, Miyazaki et al. 2011), and 
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highTMC-PLGA loaded with coumarin-6 (136 nm) NPs were found in the cortex, paracoele, the 
third ventricle and choroid plexus epithelium (Wang, Wang et al. 2010). 
Therapeutic efficacy: 
Therapeutic efficacy of certain drugs was evaluated in different animal models. T80-
PLGA NPs with entrapped estradiol (150 nm) were administered to an ovariectomized (OVX) 
rat model of Alzheimer’s disease (AD). Behavior studies and neuropathological examination 
results indicated enhanced oral delivery of estradiol to rat brain with the NPs (Mittal, Carswell et 
al. 2011). Another AD animal model APP/PS1 double transgenic mice was exposed to NPs 
introduced to investigate the delivery efficacy of Q10  loaded in TMC-PLGA NPs (146 nm) to the 
brain; behavior, senil plaque staining , and biochemical parameters were studied. Therapeutic 
efficacy of the drug was greatly enhanced when it was entrapped in TMC-PLGA NPs (Wang, 
Wang et al. 2010). Anti-tumor effect of T80- and F68-coated NPs with entrapped doxorubicin 
was demonstrated in tumor-bearing rats, and the analgesic effect of loperamide loaded T80- and 
F68-coated NPs was confirmed in mice. The maximal possible effect (% MPE) was determinied 
to evaluate the analgesic effect. F68-PLGA loaded with loperamide provided 80% MPE after 15 
min and 70% MPE for at least 60 min after administration while T80-PLGA NPS with entrapped 
loperamide reached 80% MPE and only 40% MPE after 60 min. Free loperamide showed little 
antinociceptive effect (Gelperina, Maksimenko et al. 2010). In vivo antinociception studies of 
P188-, P80-coated and PLGA-PEG-PLGA NPs with entrapped loperamide were conducted after 
i.v. administration at a dose of 0.5 mg/kg. The results of hot-plate test and formalin tests showed 
P188-coated NPs had the best antinociceptive efficacy (Chen, Hsieh et al. 2011). P188 was 
proved to be a better brain targeting agent for PLGA NPs than P80 after i.v. administration in 
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several reported studies (Kreuter and Gelperina 2008; Gelperina, Maksimenko et al. 2010; Chen, 
Hsieh et al. 2011; Kulkarni and Feng 2011). 






Brain delivery of specific ligand-conjugated nanoparticles was greatly enhanced 
compared to that of unconjugated nanoparticles (Figure 2.2). The percentage of NP dose in the 
brain reached as high as 29% for g7-PLGA NPs (169 nm) at 1.5 h after i.v. administration at a 
dose of 13.6 µg in rats (Tosi, Vergoni et al. 2010), which is the highest brain uptake reported in 
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169 nm, i.v., 13.6 μg, EF, R (Tosi, 
2010) 
197 nm, i.v., 13.6 μg, EF, R 
(Tosi, 2010) 
 
340 nm, i.v., 1.13 mg, radioactive 
drug, M (Rao, 2008) 
 
245 nm, i.v., 82.5 μg, EF, R (Gan, 
2010) 
120 nm, i.v., 1.2 mg, EF, M (Hu, 
2011) 
105 nm, i.v., 60 µg, EF, M  (Lu, 2007) 
Fig.3. Percentage (%) ligand-conjugated NPs brain uptake of dose administered versus time. 
The marked information is presented in the following order: size, administration (I.v.-
intravenous administration), dose, quantification method (EF- entrapped fluorescence 




lowest value for % dose NPs in the brain was reported for CBSA-conjugated nanoparticles: the 
uptake process was confirmed to be absorptive mediated transcytosis, and the uptake efficiency 
reached 0.3%/g brain, 2.3-fold more than that of unmodified NPs (Lu, Wan et al. 2007). 
Different peptides functionalized nanoparticles were constructed to activate receptor-mediated 
endocytosis, which could enhance brain-targeted delivery. Four synthetic opioid peptides 
(Costantino, Gandolfi et al. 2005), a 120 amino-acid-peptide screened from in vivo phage display 
(Li, Peng et al. 2011), trans-activating transcriptor (TAT) peptide (Rao, Reddy et al. 2008) and a 
simil-opioid peptide (g7) (Tosi, Vergoni et al. 2010) were successfully conjugated to PLGA/PLA 
NPs and the conjugation was showed to improve brain delivery of nano-carriers. Transferrin (Tf) 
is another commonly used ligand for targeted brain delivery as Tf was proven to interact with 
corresponding receptor in the brain to induce receptor-mediated transcytosis (Chang, Jallouli et 
al. 2009; Gan and Feng 2010; Jain, Chasoo et al. 2011; Kuo, Lin et al. 2011). Other specific 
ligands conjugated to successfully increase brain uptake included transferring antibody (Carroll, 
Bhatia et al. 2010), sialic acid residue (Tosi, Vergoni et al. 2010), lactoferrin (Hu, Shi et al. 
2011), poly-(γ-glutamic acid) (Kuo and Yu 2011), and DNA aptamer (Guo, Gao et al. 2011).  
In all cases, targeting ligand succeeded to provide a receptor-mediated endocytosis of 
surface functionalized NPs, and brain uptake of modified NPs greatly increased (the highest one 
reached 29%) when compared to unconjugated NPs (<1%) after i.v. administration.  
Location of NPs in the brain: 
Fluorescence studies on the location of NPs in the brain demonstrated that three peptide-
derived NPs (162-211 nm) with covalently linked fluorescent probe (Costantino, Gandolfi et al. 
2005), TAT-PLA NPs with coumarin-6 as fluorescent marker (340 nm) (Rao, Reddy et al. 2008), 
tetramethylrhodamine-linked SA-g7-PLGA NPs (154 nm) (Tosi, Vergoni et al. 2010) and Tf-
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PEG-PLGA (121 nm) with entrapped rhodamine 6G (Jain, Chasoo et al. 2011) all reached 
cerebral parenchyma, which proved the ability of targeted NPs to cross the BBB. 
Therapeutic efficacy: 
Besides direct-observation of nanoparticles in the brain, several experiments were 
performed to prove enhanced brain delivery of the drug in disease animal models. The 
antinociceptive effects of SA-g7-PLGA NPs with entrapped loperamide was tested and MPE 
values maintained at 30-50% for 15h while the effect of loperamide loaded g7-PLGA NPs was 
57% for only 5h after administration (Tosi, Vergoni et al. 2010).Therapeutic effect of urocortin 
(UCN) loaded in Lf-NPs on 6-OHDA rat model of Parkinson’s disease was investigated. The 
behavior, immunohistochemistry and transmitter contents of the brain results confirmed the 
improved efficiency of UCN loaded Lf-NPs to attenuate the striatum lesion compared to the 
control group after i.v. administration (Hu, Shi et al. 2011).  In vivo anti-tumor efficacy was 
carried out on rats bearing glioma xenografts and rats bearing intracranial C6 gliomas. After 
intravenous administration of paclitaxel (PTX) loaded aptamer-conjugated NPs (Ap-PTX-NP), 
tumor size, body weight and survival time were recorded to evaluate the anti-glioma efficacy. 
The average tumor inhibition of Ap-PTX-NP and free Taxol for tumor volume was 81.6 and 
68.6%, and for tumor weight was 79.3 and 48.2%. The survival time of Ap-PTX-NP treated rats 
bearing glioma was 7 days longer than PTX treated group and 13 days longer than saline treated 
group (Guo, Gao et al. 2011). In all cases, therapeutic effect of the drug was greatly improved 
after the drug was incorporated into surface-modified NPs. 
2.4. Conclusions 
In recent years, polymeric nanoparticles were well investigated and the technology has 
developed at a rapid pace. PLGA/PLA nanoparticles (100-300 nm) have been proven as potential 
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carriers for drug delivery across the BBB with advantages of both enhanced drug efficiency and 
safety. NPs offer superior alternatives to oral and i.v. administration of free drugs that cannot 
otherwise transport across the BBB, which is definitely a significant breakthrough for brain 
delivery.  
For in vitro studies, cytotoxicity, cellular uptake, mechanism of uptake, and therapeutic 
efficiency were investigated. In vitro toxicity studies showed no toxicity of PLGA NPs for doses 
of 0.075 to 8000 μg/ml. The cellular uptake efficiency was greatly improved with the 
modification of PLGA NPs. The permeation percentages of loperamide entrapped F68- and T80 
surface modified PLGA NPs (21% and 14.5%) in rat brain endothelial cell line and C6 co-
cultures were significantly increased compared to loperamide loaded unmodified PLGA NPs 
(4.5%) and free loperamide (0.4%) (Chen, Hsieh et al. 2011). A significant decrease in cell 
viability of glioma cells treated with drug loaded modified NPs was proven, supporting the 
improved uptake and efficacy of drugs loaded in PLGA NPs. Endocytosis mechanisms were 
unveiled for specific systems. For example, the uptake of Lf-TPGS-PLA NPs was proved to be 
clathrin mediated endocytosis and endocytosis of Tf-PLGA NPs was confirmed as caveolae 
mediated endocytosis. 
In vivo biodistribution studies were conducted in either rats or mice after NP 
administration (oral, carotid artery and i.v.), to determine brain uptake of various NPs. 
PLGA/PLA NPs showed very low (<1%) brain uptake without modification, which alleviated 
the concern that unmodified PLGA/PLA NPs used for applications other than CNS delivery 
cross the BBB. Surface modifications of PLGA NPs such surface-coating and the addition of 
targeting ligands improved brain delivery of drugs compared with unmodified PLGA NPs. 
Ligands, covalently linked to the surface of the particles improved brain uptake of NP the most. 
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The highest brain uptake was achieved by g7-PLGA NPs (169 nm) (14% /g tissue) which were 
characterized as instant high brain delivery with a short retention time (Tosi, Vergoni et al. 2010). 
The presence of modified PLGA/PLA NPs within rats/mice brain parenchyma after systemic 
administration was confirmed by microscopy studies. Besides brain uptake, behavior studies of 
treated animals and therapeutic efficacy studies after NP administration supported the 
enhancement of brain delivery of modified PLGA NPs as compared to unmodified NPs or free 
drug.  
It was evident that in vitro and in vivo information on delivery of drugs with PLGA/PLA 
NPs (100-300 nm) to CNS was available and sufficient to confirm the enhanced brain uptake and 
therapeutic efficacy of certain drugs entrapped in PLGA NPs. These studies suggest that multiple 
strategies could be applied to construct an optimum brain delivery system based on PLGA. 
However, the literature is lacking in several aspects. First, in vivo long-term toxicity studies of 
modified NPs including their effects on the brain were not found in the literature and should be 
evaluated. It is important to assess the safety and potential risks of brain-targeted PLGA/PLA 
NPs, especially for systems that are associated with highly improved brain uptake. Second, the 
amount of data is not sufficient in the literature to understand NP brain uptake as a function of 
concentration of the NPs administered, or their properties (size, charge). It is unclear if brain 
uptake of NPs is concentration-dependent, and if saturation would be reached as the dose 
administered was increased. Size appears to affect uptake, with small NP size being more 
favorable, but it is hard to compare uptake across studies when other parameters (charge, method 
of administration or detection) are not uniform. Brain uptake is also enhanced for NPs that are 
more hydrophobic and if they carry a positive charge. However, because of the lack of 
systematic studies, comparisons between systems reported in the literature so far are not possible. 
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Lastly, information on the location of NPs modified by different strategies in the brain after they 
cross the BBB is not readily available, as well. Location of the NPs within the brain may affect 
the efficacy of the entrapped drug.  
It is clear that even though much is yet to be done to understand brain uptake of 
polymeric NPs, and their impact on drug efficacy and safety, the design of safe nano carriers for 
improved drug delivery to certain location in the brain, and an enhanced drug efficacy and low 
toxicity is certainly possible. Design of such targeted delivery systems to the CNS will aid in 
treatment of CNS diseases. 
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CHAPTER 3    WHEAT GERM AGGLUTININ CONJUGATED PLGA 




Parkinson’s disease (PD), a neurodegenerative disorder of the central nervous system, is 
the second most common neurodegenerative disease after Alzheimer’s disease (Alves, Forsaa et 
al. 2008). PD impairs motor skills, cognitive processes, and other body functions (Wolters 2009). 
According to current studies, nigral dopamine deficiency-related dysfunction of the basal ganglia 
is regarded as the cause of the major PD symptoms (Wolters 2009).  
As dopamine cannot across Blood Brain Barrier (BBB), current treatments are effective 
at managing motor symptoms through the use of levodopa (L-DOPA), dopamine agonists and 
Monoamine oxidase B (MAO-B) inhibitors (Schapira 2005). However, delivery of these drugs is 
quite poor. For instance, only 5-10% of L-DOPA orally administered is able to cross the blood-
brain barrier. The remaining is often metabolized to dopamine by enzymes, i.e. decarboxylases, 
in the stomach or blood, causing a wide variety of side effects, such as nausea, dyskinesias and 
stiffness(Factor 2008). Many severe side effects may be induced by the undesirable distribution 
of any antiparkinsonian drug in health tissues, including psychiatric distribution and 
dyskinesias(Ceravolo, Frosini et al. 2009). This greatly limits the maximum allowable dose of 
the drug.  
To reduce the harmful side effects of the undesirable accumulation of drugs, improved 
delivery systems must be developed for treatment of PD. Among the advanced technology, 
nanotechnology appears promising in developing drug delivery systems of targeting and 
controlled-release characteristics beneficial for drug delivery such as L-DOPA(Linazasoro 2008). 
The advantages of nanoparticles as drug delivery systems include time controlled drug delivery, 
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reduced drug toxicity, improved bioavailability and enhanced therapeutic efficacy and 
biodistribution of the drug(Ravi Kumar 2000). Polymeric nanoparticles range in size from about 
10-1000nm (Kreuter 2001), and can be modified with different ligands to create a smart targeting 
delivery system. For example, to further improve the delivery efficacy of L-DOPA; a targeted 
delivery system should be designed to enhance brain delivery of this drug. Wang’s group 
synthesized trimethylated chitosan modified PLGA nanoparticles for the delivery of drugs to the 
brain, and showed that the conjugated nanoparticles were able to cross the blood brain barrier 
with low toxicity (Wang, Wang et al. 2010). Hu K’s group developed lactoferrin conjugated 
polyethylene glycol-polylactide-polyglycolide (PEG-PLGA) nanoparticles which targeted mice 
brain 3 fold more than empty nanoparticles (Hu, Shi et al. 2011). Endocytosis of Transferring-
coated PLGA nanoparticles by BBB endothelial cells was found 20-fold higher than that of blank 
PLGA nanoparticles(Chang, Jallouli et al. 2009).  
Lectins have been conjugated with drugs to enhance drug absorption in the 
gastrointestinal tract or to target drug to a certain kind of cells including intestine cells, cancer 
cells and brain endothelial cells (Ratzinger, Wang et al. 2010). Chunxia Wang’s group has 
designed wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular 
delivery of paclitaxel to colon cancer cells. Conjugated PLGA nanoparticles demonstrated 1.67 
fold in the Caco-2 (30% of uptake) and 1.48 fold HT-29 (40% of uptake) cells more than non-
targeted nanoparticles (Wang, Ho et al. 2010). Xiaoling Gao et al. developed an enhanced 
delivery of vasoactive intestinal peptide with nanoparticles conjugated with wheat germ 
agglutinin (Gao, Wu et al. 2007). The delivery of incorporated vasoactive intestinal peptide by 
PLGA nanoparticles and WGA conjugated PLGA nanoparticles was greatly improved 3.5 to 4.7 
folds and 5.6 to 7.7 folds respectively when compared to the free drug. Wen Z. et al conjugated 
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odorranalectin (OL) to PEG-PLGA nanoparticles to improve nose-to-brain drug delivery in the 
treatment of central neuron systems disorders(Wen, Yan et al. 2011). 
Various lectins have been used as components of oral drug delivery systems including 
tomato lectin, peanut agglutinin and wheat germ agglutinin (WGA) (Gao, Wu et al. 2007). WGA 
comes from Triticum vulgaris, and shows a special affinity to N-Acetyl-glucosamine (GlcNAc) 
and sialic acid which are the major glycoproteins on the surface of most cells. WGA is regarded 
as a promising carrier for oral drugs because of its biochemical characteristics and non-toxic 
property(Irache, Durrer et al. 1994).    
Several protocols have been developed to conjugate WGA with PLGA nanoparticles. 
Liu’s group coupled WGA to PLGA nanoparticles by activating the hydroxyl group of poly 
(vinyl alcohol) (PVA) with glutaraldehyde (Liu, Wang et al. 2010). Another commonly used 
method is to activate the free carboxyl groups on the nanoparticle suface by carbodiimide 
reagents and then linking it with amino groups of WGA (Weissenbock, Wirth et al. 2004; Mo 
and Lim 2005; Yin, Chen et al. 2006). However, surface functionalization of nanoparticles could 
be hard to achieve as limited number of carboxyl groups is available and might be masked due to 
the presence of surface additives (Yin, Chen et al. 2006).Yin’s group synthesized a novel WGA-
PLGA conjugate by covalently linking the amine groups of WGA with the carbodiimide-
activated carboxylic group of PLGA, and prepared nanoparticles with these conjugates (Yin, 
Chen et al. 2006).  
Caenorhabditis elegans (C.elegans) is a model commonly used to study neuron drug 
delivery (Braungart, Gerlach et al. 2004; Nass, Merchant et al. 2008) as the hermaphroditic 
C.elegans organism contains only eight dopamine neurons, thereby largely simplifying a wide 
array of investigations (Nass, Hall et al. 2002). Worms that express the green fluorescent protein 
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(GFP) can be used when the in vivo visualization of cellular processes is necessary. Other 
advantages of using C.elegans in laboratory studies include a short generation time, and ease of 
growth (Wood 1988; Riddle 1997; Wintle and Van Tol 2001).  
 The hypothesis of this study was that WGA-conjugated PLGA nanoparticles will 
enhance targeted delivery of PLGA nanoparticles to the neurons of C. elegans. WGA conjugated 
PLGA nanoparticles were synthesized and characterized in terms of physical properties and 
conjugation efficiency. The ability of the nanoparticles to target the neurons and the effect of the 
nanoparticles on pumping rate, travel distance, size of C. elegans, as well as area and intensity of 
DAergic neurons were tested. Co-localization of DAergic neurons and PLGA-tWGA 
nanoparticles was demonstrated by fluorescent images. 
3.2. Objectives 
1. Synthesis of TRITC conjugated poly (lactide-co-glycolide) nanoparticles (PLGA-t NPs) 
and tWGA conjugated PLGA nanoparticles (PLGA-tWGA NPs) by emulsion evaporation 
method, with PVA as surfactant. 
2. Charaterization of PLGA-t NPs and PLGA-tWGA NPs in terms of size, size distribution, 
zeta potential (DLS), morphology (TEM) and conjugation efficiency. 
3. Analysis of the effect of tWGA, PLGA-t NPs and PLGA-tWGA NPs on pumping rate, size, and 
number, intensity and area of GFP-DAergic neurons with C.elegans. 
3.3. Materials and methods 
3.3.1. Chemicals and materials 
PLGA 50:50 with an average molecular weight of 45 000–75 000, PVA with an average 
molecular weight of 30 000–70 000, 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-
hydroxysuccinimide (NHS), Ethylenediamine, Diethylether, Dimethyl sulfoxide (DMSO), Ethyl 
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Acetate, tetrahydrofuran (THF) and Ethanol were purchased from Sigma-alorich (St.louis, USA). 
TRITC was purchased from Thermoscientific (IL, USA). DCM was obtained from Mallinckwdt, 
chemicals (NJ, USA). TRITC-WGA and N-acetyl-glucosamine were acquired from Vector 
Laboratories, INC (CA, USA).  
3.3.2. Preparation of TRITC-labeled PLGA conjugates 
 
For preparation of fluorescent PLGA nanoparticles, TRITC was covalently conjugated to 
the PLGA chains by a carbodiimide method (Figure 3.1) (Chung, Kim et al. 2010)
 
. In this 
method, 200 mg PLGA was dissolved in 10ml DCM, and 4.1mg DCC (20 µmol) and 2.3 mg 
NHS (20 µmol) were added to activate the carboxylic groups of PLGA. Then, 10 fold excess 
Figure 3.1 PLGA-t conjugation reactions 
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ethylenediamine (3.3 µL, 50 µmol) was added to convert the succinimidyl ester group into a 
primary amine group. Next, 4.0 mg TRITC was added at room temperature to the PLGA. The 
product was precipitated in excess ethanol to remove unreacted TRITC, and then dried under 
vacuum. 
3.3.3. Sythesis of PLGA-WGA conjugates 
 
To conjugate TRITC-WGA (tWGA) with PLGA, a similar carbodiimide method was 
performed (Figure 3.2) (Yin, Chen et al. 2006). First, 100 mg PLGA was dissolved in 10 ml 
tetrahydrofuran (THF). Then, 2 ml PBS (0.01 M, pH 6.0) with 3.88 mg 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and 2.88 mg N-hydroxysulfosuccinimide (NHS) 
were injected. The activation of PLGA was carried out at room temperature overnight. 
Afterwards, the mixture was dried under vacuum, and washed with 3 ml nanopure water to 
remove excess carbordiimide reagents three times. Then, 5 mg tWGA was added and incubated 
Figure 3.2 PLGA-tWGA conjugation reation 
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at room temperature for three days. Free tWGA was removed by water-dichloromethane (DCM) 
extraction performed three times. The product was dried under vacuum for 2 days. 
              
3.3.4. Synthesis of PLGA-t nanoparticles 
An amount of 20 mg of TRITC-labeled PLGA and 20 mg non-tagged PLGA were 
dissolved in 2 ml dichloromethane to form an organic phase. An aqueous phase was formed with 
0.3% PVA dissolved in nanopure water. Then, the organic phase was added in droplets to the 
aqueous phase, and the emulsion was sonicated in an ice bath at 4 ◦C with a probetype sonicator 
(VC505, Sonics & Materials Inc., Wilmington, NC, USA) set at 750 W for 10 min, in pulse 
mode at 38% amplitude. Dichloromethane was evaporated under vacuum and nitrogen flow for 5 
min in a rotoevaporator (Buchi R-124, Buchi Analytical Inc., New Castle, DE, USA). Following 
synthesis, centrifugation was carried out to remove the excess surfactant. After purification, 
nanoparticles were kept for 2 h at 80 °C and freeze-dried at 4°C under 110 mm Hg of vacuum for 
48 h in a Freezone 4.5 (Labconco Corp., Kansas City, MO, USA). Trehalose was be added to the 
nanoparticles suspension before precooling at a ratio of 1:1 (w/w) relative to the amount of 
nanoparticles. Finally, the lyophilized samples were stored in desiccators placed in the 
refrigerator for further use. 
3.3.5. Synthesis of PLGA-tWGA nanoparticles 
PLGA-t nanoparticles and PLGA-tWGA nanoparticles were prepared by an emulsion 
evaporation method(Zigoneanu, Astete et al. 2008). First, 40 mg PLGA-tWGA conjugates were 
dissolved in 2 ml DCM as organic phase. Then the organic phase was injected to 10 ml 0.3 % 
polyvinyl alcohol (PVA) in an ice-bath with sonication (VC505, Sonics & Materials Inc., 
Wilmington, NC, USA) for 10 minutes, followed by removing organic solvents under vacuum 
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for 5 minutes. Excess PVA was removed by dialysis for 2 days. Trehalose was added at a ratio of 
1:1. The final products were lyophilized for 2 days and stored at 4 °C. 
3.3.6. Characterization of nanoparticles 
An amount of 5.0 mg nanoparticles was resuspended in nanopure water. The average size, 
polydispersity index (PDI) and zeta potential of the resuspension were determined by dynamic light 
scattering (DLS). The morphology of nanoparticles was determined by transmission electron microscopy. 
The amount of TRITC conjugated to PLGA-t NPs was determined by using a spectrofluorometer 
(Wallac 1420 VICTOR, Perkin Elmer Inc., Waltham, Massachusetts, USA). The volume of 0.1 mL 
standard TRITC solution was pipetted to each well. The intensity of the standard solution was measured 
at different concentrations at the absorbance 531/572 nm with nano pure water as blank. The amount of 1 
mg PLGA-t NPs was resuspended in 1 ml nano pure water and measured under the same condition. The 
concentration of TRITC conjugated on PLGA NPs was determined according to the standard curve of 
TRITC. 
The conjugation efficiency of PLGA-tWGA NPs is determined by BCA protein assay (BCA 
protein assay kit, Thermo Scientific, Rockford, IL, USA) (Mo and Lim 2005). An enhanced test tube 
protocol with working range at 5-250 µg/ml was used. A series of albumin (BSA) were prepared for a 
standard curve. Accurately weighed PLGA-tWGA NPs (5 mg) were dissolved in 1 mL nano pure water. 
The volume of 0.1 ml of each standard BSA solution, PLGA-tWGA solution were pipetted to each 
labeled tube, and 2.0 ml fresh prepared BCA working reagent was added to each tube. The mixtures were 
incubated at 60 °C for 30 minutes, and cooled to room temperature. The absorbance of all the samples 
was measured with the spectrophotometer set at 562 nm within 10 minutes. A cuvette filled only with 
water was set as blank. The protein concentration was determined according to the standard curve and it 
was expressed as the weight of WGA relative to the weight of nanoparticles (µg WGA/ mg NPs). 
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3.3.7. Effect of targeting on C.elegans 
Age synchronized C. elegans was cultured in agar dish, and fed with freshly cultured E. coli 
(OP500) and Luria-Bertani Medium (LB) in the presence of the treatments including tWGA, PLGA-t 
nanoparticles, PLGA-tWGA nanoparticles. The applied treatments were compared with the control (no 
treatment). Concentration of the free tWGA used as a control was determined according to the 
conjugation efficiency of PLGA-tWGA NPs. 
The following characteristics of C. elegans were monitored during their life span, pumping rate, 
body size, and on the number, area and intensity of DAergic neurons. 
3.3.7.1.  Pharyngeal pumping rate  
Animals were examined three times a week using a stereomicroscope (Nikon SMZ-U). The 
pumping rate of five worms was recorded manually for 1 min. The pumping rate data was compared with 
the control. 
3.3.7.2.  Size of C. elegans 
 C. elegans BZ555 was cultured in agar dishes at 20C and fed with freshly cultured E. coli 
(OP50) or with E.coli mixed with nanoparticles for 10-15 days. Digital video was captured daily using a 
digital camera (Redica 4000R) and a stereomicroscope (Nikon SMZ-U). Offline analysis was performed 
with ImagePro (Mediacy) to measure length over time (n=10-20).      
3.3.7.3.  Number, intensity, and area of GFP-DAergic neurons and co-localization  
Staining was performed to locate PLGA-t NPs and PLGA-tWGA NPs as follows. After pumping 
rate reached a level lower than 60/min, worms treated with PLGA-t NPs and PLGA-tWGA NPs were 
washed with S-Basal (1ml /dish), fixed with 4% paraformaldehyde for 30 min, washed with PBS, and kept 
at 4C overnight. 10 µl of the sample and 10µl of Fluoromount-G (anti fading mounting medium) was 
applied on to a glass slide and mounted with a cover glass. Micrographs of the slides were taken using a 
fluorescence microscope (Nikon Eclipse Ti-S) equipped with a digital camera Retiga 400-R, and 
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FITC/TRITC filters. The co-localization of the GFP-DAergic neurons (green) and nanoparticles (red) was 
determined by imaging.  
Number, fluorescent area (µm
2
), and mean intensity of DAergic neurons were quantified with NIS 
analyze, and compared between control group and treated groups (n=20). The number and area of GFP-
DAergic neurons per animal were indicated by the appearance of GFPs expressed in eight DAergic neurons. 
The intensity of DAergic neurons was determined by the fluorescent intensity of GFP per neuron per 
animal. 
A time study was also carried out to evaluate the effect of GFP-DAergic neurons over time. A 
number of 5 worms was picked out every other day, stained on a glass slide, and number, area, and 
intensity were determined with the method described above.  
Co-localization of fluorescent nanoparticles to labeled GFP-DAergic neurons, and nanoparticle 
routing was identified with a Zeiss LSM510 laser scanning microscope.  
3.3.8. Statistics  
Ancova Test in SAS was used to assess significance of pumping rate, body size and time 
study. Statistics of intensity, area and number of GFP-DAergic neurons were performed by 
anova test in SAS. Significant difference was declared at p-values lower than 0.05. 
3.4. Results and Discussion 
3.4.1. Nanoparticle physical-chemical characteristics 
In this study, both fluorescent nanoparticles and WGA conjugated nanoparticles were 
prepared. The main characteristics of PLGA-t NPs and PLGA-tWGA NPs are summarized in 
Table 3.1. Mean diameters of these nanoparticles ranged from 208 nm (PLGA-t NPs) to 221 nm 
(PLGA-tWGA NPs) with a polydispersity index of 0.11 and 0.08, respectively. These 
nanoparticles were negatively charged, and zeta potential ranged from -34.5 mV (PLGA-t NPs) 
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to -42.0 mV (PLGA-tWGA NPs) at neutral pH. The amount of TRITC conjugated PLGA-t NPs 
was 1.2 µg /mg NP. Morphology of the NPs was examined under a transmission electron 
microscope. The TEM images showed that all nanoparticles appeared relatively spherical in 
shape (Figure 3.3).  
Table 3.1 Physical characteristic of nanoparticles 





(µg WGA /mg NP) 
PLGA-t NP 208.0±2.9 0.11±0.01 -34.5±0.5 - 
PLGA-tWGA NP 221.0±0.1 0.08±0.01 -42.0±0.4 4.9±1.1 
 
 
3.4.2. WGA conjugation efficiency 
After freeze drying, both nanoparticle suspensions PLGA-t and PLGA-tWGA displayed a 
pink color which indicated success of conjugation. The conjugation efficiency was 4.9 µg 
WGA/mg NP as determined by spectrophotometry (Table 1). The conjugation efficiency of 
(a) (b) 
Figure 3.3 TEM pictures of (a) PLGA-t NP at magnificent of 33,000× and (b) 




WGA was lower compared to another method which coupled WGA to the surface of already 
synthesized PLGA nanoparticles (18.1±2.5µg WGA/mg nanoparticles) (Wang, Ho et al. 2010), 
but of similar order of magnitude. TRITC labeled WGA was used in the synthesis, rather than 
free WGA, in order to visualize nanoparticles and in the TRITC-WGA construct, amine groups 
of WGA, reaction groups important for the PLGA conjugation, were mostly occupied by TRITC, 
which might lead to low conjugation of TRITC-WGA to PLGA. 
3.4.3. Effect of targeting on C. elegans 
In order to measure the ability of WGA conjugated PLGA nanoparticles (PLGA-tWGA 
NPs) to target neurons in C. elegans, the effect of PLGA-tWGA nanoparticles on C. elegans 
behavior was tested and compared with that of free tWGA. PLGA-t NPs were also tested to 
evaluate the effect of unconjugated PLGA NPs. The following characteristics were monitored in 
C. elegans during its life span (about 14 days), pharyngeal pumping rate, size (length/width), 
number, area and intensity of GFP-DAergic neurons, and transport of nanoparticles (co-
localization).   
3.4.3.1.  Pharyngeal pumping rate  
E. coli (OP50), food for C.elegans is ingested by the pharynx, a neuromuscular organ in 
the head (Wolkow 2006). Feeding behavior of C.elegans can be monitored by counting the 
contraction rate of the pharynx muscle.  
It is well known that the pharyngeal pumping rate slows as the pharynx muscles 
deteriorate during aging(Wolkow 2006). It was not surprising therefore that pumping rate of the 
control and treated groups decreased over the 14 days study (Figure 3.4). Pumping rate for the 
control group decreased from 282/min to 18/min in 15 days while pumping rate in 1.0 mg/ml and 
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2.0 mg/ml PLGA-t NPs treated groups decreased from 280/min-288/min to 18/min-19/min over 
the same period of time (Figure 3.4a). Statistically, no significant difference was found in the 
pumping rate between the control group and the treated groups (P>0.05). More than half of 
worms treated with a higher concentration of PLGA-t NPs, 3.0 mg/ml PLGA-t NPs were found 
dead within 8 days. However, C.elegans treated with PLGA NPs that was not covalently linked 
with TRITC at the same concentration survived the same life span as the control group. The 
short life span of PLGA-t treated worms at a high concentration indicated that the high amount 





Figure 3.4 Pharyngeal pumping rate of C. 
elegans treated with (a) PLGA-t NPs at 
two concentrations, 1 and 2 mg/ml (b) 
free tWGA at five concentrations, 5, 10, 
15, 30 and 40 µg/ml (corresponding to 1, 
2, 3, 6 and 8 mg/ml NPs, respectively), 
list, and c) PLGA-tWGA NPs at five 





Pumping rate of the C.elegans treated at five concentrations of free tWGA decreased from 
241/min to 81/min while that of control group decreased from 239 to 109/min within 12 days 
(Figure 3.4b). For PLGA-tWGA NPs treated group, pumping rate was reduced from 238/min to 
63/min over 12 days. The values for the pumping rate are in good agreement with the literature, 
which reports that in young adults, the parynx pumps 200-300 times/min and declines greatly 
with aging (Chow, Glenn et al. 2006). Several factors might contribute to the decrease of 
pumping rate including contraction related muscle deterioration in the pharynx and microbial 
infection (Chow, Glenn et al. 2006). Statistically, compared with the control group, a significant 
difference was found only at the highest concentration of free tWGA, 40 µg/ml tWGA; for all 
other tWGA concentrations pumping rate was not significantly different than the control. For 
PLGA-tWGA NPs treated animals, three groups treated with the highest concentrations of NPs, 
3, 6, and 8 mg/ml PLGA-tWGA NPs were significantly different from the control (P<0.05).  
To facilitate comparison between treatments, worms were treated with PLGA-tWGA NPs 
and corresponding concentrations of tWGA. No significant difference was observed except 
between 15.0 μg/ml tWGA treated group and the equivalent 3.0 mg/ml PLGA-tWGA NPs 
treated group (P=0.0135), and between 30.0 μg/ml tWGA and the equivalent 6.0 mg/ml PLGA-
tWGA NPs treated groups (P=0.0017). This result confirmed that while free tWGA affected 
pumping rate solely at the highest concentration (40µg/ml), PLGA-tWGA NPs showed a 
significant effect on pumping rate starting at 3 mg/ml, an equivalent of only 15 ug/ml tWGA. At 
the smallest tWGA concentrations, the targeting agent did not have an effect on pumping rate, 
whether in free or conjugated form. It is apparent that a minimum tWGA is required to have an 
effect on the neurons, and that this effect is noted at lower concentrations for tWGA when 
conjugated to PLGA nanoparticles than in free form. 
78 
 
As dopamine neurons are mechanosensory neurons, involved in locomotion, feeding, egg-
laying and so on, pumping rate could be used as an indicator of the effect of the nanoparticle 
treatment on dopamine neurons (Collins, Huang et al.). The significant difference in pumping 
rate caused by free tWGA only at the highest concentration (40µg/ml) and PLGA-tWGA NPs at 
three highest concentrations (3, 6, and 8 mg/ml equivalent to 15, 30, and 40 ug/ml tWGA) 
compared to control group indicated that tWGA conjugated to PLGA NPs affected more 
pumping rate of the worms than the equivalent concentration of free tWGA. 
3.4.3.2.  Size of C. elegans 
Both length and width of C.elegans were measured using ImagePro and the values were 
compared to size of the control group (Figure 3.5). Measurements were performed three days 
after the worms were age synchronized and incubated at 20 ◦C. Length and width of all groups 
were found to be in average 480 µm in length and 150 µm in width. Both length and width of 
C.elegans increased during aging. For the control group, size increased to 900 µm in length and 
250 µm in width over a period of 14 days. C. elegans is reported to measure up to 1000 µm at 
adulthood with variations in size due to the software used in the measurement and type of worms 
studied (Meyer, Lord et al. 2010). 
Size of the worms treated with PLGA-t NPs increased from 423-432 µm (day 1) to 759-
855 µm (day 14) in length, and from 173-194 µm to 279-287 µm in width (Figure 3.5a), whereas 
length of the control group increased from 457±4 µm (day 4) to 819±3 µm (day 14). Width of 
control group increased from 180 µm to 280 µm from day 4 to day 14. Statistics showed that for 
both length and width of PLGA-t NPs treated group, no significant difference was found at both 
concentrations tested (P>0.5). The experiments were done at the lowest two concentrations of 
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PLGA-t NPs to avoid early death of animals as observed at the highest concentrations of TRITC 
labeled PLGA NPs, noted earlier.  
 Length of tWGA treated worms were initially 437-473 µm at day 4, and it increased to 
866-922 µm at day 14 (Figure 3.5b), whereas PLGA-tWGA treated groups increased in length 
from 416-473 µm to 692-899 µm (Figure 3.5c). Width from day 4 to day 14 of the three 
concentrations of tWGA treated groups increased from 80-197 µm to 262-300 µm (Figure 3.5b) 
while the length of three concentrations of PLGA-tWGA treated groups varied from 186-191µm 
to 252-277 µm (Figure 3.5c). Most of tWGA and PLGA-tWGA NPs treated worms showed 
significantly different length and width when compared to the control group. The presence of 
tWGA in free or conjugated form affected length of C. elegans, but no specific trend was 
identified. The size increased or decreased depending on the treatment and the size changes were 
found minimal.  
For C.elegans, growth is not controlled by the dopamine neurons, instead body size is 
mainly affected by genetic factors and environmental factors, of which food and temperature are 
most important (So, Miyahara et al. 2011). Hence, body size is not an indicator of targeting, but 
it could be an indicator of treatment toxicity. The trend of size increasing versus time did show a 
significant difference between control and nanoparticles treated group. However, at each time 
point, both width and length varied only slightly relative to the control. For all treatments both 
length and width stayed within the normal body size of C.elegans, and hence tWGA and PLGA-









Figure 3.5 Size (length/width) of control group and (a) two concentrations of PLGA-t 
NPs treated groups, (b) five concentrations of  tWGA NPs (5.0 µg WGA/mg NPs) 
treated groups, and (c) five concentrations of  PLGA-tWGA NPs (5.0 µg WGA/mg 




3.4.3.3.  Area, mean intensity and number of GFP-DAergic neurons 
The C. elegans strain BZ555 was used in this study because it expressed green 
fluorescent protein in the dopamine neurons, allowing visualization of DAergic neurons. If 
nervous system of C.elegans shows minimal changes during aging (Collins, Huang et al.), then a 
change in the number, area or intensity of the DAergic neurons of nanoparticle-treated worms 
could be an indication of successful delivery of the nanoparticles to the neurons.Fluorescent 
intensity and area of GFP-DAergic neurons were used as an indicator of the presence of 
fluorescent nanoparticles transported to GFP-DAergic neurons.  
The number of GFP-DAergic neurons of tWGA treated groups was in the range of 6.0-
6.6, and for the PLGA-tWGA NPs treated group the number of identifiable neurons was 6.0-6.4, 
similar to the control (6.2/animal). It is known that C. elegans hemaphrodites have eight DAergic 
neurons, however in average only six neurons were identifiable in the strain BZ555 after aging 
with the fluorescence microscopic technique described earlier. Statistically, no significant 
difference was observed in the number of neurons for all concentrations when compared to the 
control (P>0.5) (Figure 3.6a).  
For tWGA treated groups, area of GFP-DAergic neurons was 5.6– 7.8 µm
2
   (Figure 
3.6b). No significant difference was found between the neuron area of tWGA treated group at 
five concentrations (5.0, 10.0, 15.0, 30 and 40 µg/ml (5.6-7.8 µm
2
) and that of the control (7.3 
µm
2
). PLGA-tWGA NPs showed a significant effect on area of GFP-DAergic neurons compared 
to the control. Area of GFP-DAergic neurons was significantly lower for the PLGA-tWGA NPs 
treated worms at 1.0 mg/ml (4.9 µm
2
) and 3.0 mg/ml (4.7 µm
2
) (P=0.04, 0.03 respectively). The 
lowest value reached was 4.5 µm
2







 Figure 3.6 (a) Number, (b) mean area and (c) mean intensity of GFP-
DAergic neurons. * P<0.05 
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Figure 3.7  
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For tWGA treated group, the average intensity of GFP-DAergic neurons decreased from 
11,448 (control) to 10,970-11,949 (P>0.08) (Figure 3.6c). The intensity of GFP-DAergic neurons 
over five concentrations of PLGA-tWGA NPs (1, 2, 3, 6, and 8 mg/ml) decreased in a dose 
dependent manner from 11,448 (control) to 9,941 -10,763, but no significant difference was 
found (P>0.05) between the treatments and the control. 
The comparison between PLGA-tWGA NPs and same amount of tWGA was also 
performed. No significant difference was found in the number of neurons between PLGA-tWGA 
NPs treatment and the equivalent amount of free tWGA treatment. As for the area, 2.0 mg/ml 
and 3 mg/ml PLGA-tWGA NPs showed a greater effect on decreasing the area of the neurons 
than the equivalent amount of free tWGA (P=0.03 and 0.006 respectively). In terms of intensity 
of GFP-DAergic neurons, no significant difference was observed except for the 3.0 mg/ml 
PLGA-tWGA NPstreated groups and equivalent concentration of tWGA (P=0.01). 
The concentration-dependent trend of all treatments was assessed by comparing the 
number, area and intensity of GFP-DAergic neurons change as a function of concentration 
(Figure 3.7). Number of GFP-DAergic neurons for both treatments maintained at similar level 
over the concentration range studied (Figure 3.7a, P=0.6). Area of GFP-DAergic neurons of 
worms treated with tWGA and PLGA-tWGA NPs showed a dose dependent decrease (Figure 
7b). PLGA-tWGA NPs treated group showed a significant decrease compared to tWGA treated 
worms (P<0.0001). Dose dependent trend was also found for the intensity of GFP-DAergic 
neurons (Figure 3.7c). After treatment with tWGA, intensity of GFP-DAergic neurons slightly 
decreased while PLGA-tWGA NPs treated group showed a much more pronounced dose-
dependent decrease (P<0.0001). 
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The number and intensity of GFP DAergic Neurons did not change for all treatments 
compared to the control group, whereas the area changed for PLGA-tWGA NPs, indicating that 
particles did reach the neurons and had an effect that resulted in a smaller area of possibly 
damaged DAergic neurons. PLGA-tWGA NPs may damage the DAergic neurons, especially at 
the highest concentrations (> 3mg/ml) with an effect on pumping rate as seen earlier,. It was 
implied that the significant decrease of pumping rate for the PLGA-tWGA NPs treatments at the 
highest concentrations was the result of targeted transport of PLGA-tWGA NPs to DAergic 
neurons. The decrease in the area of the GPF DAergic neurons of PLGA-tWGA treated worms, 
confirmed the findings, supporting the targeting ability of the PLGA-tWGA NPs. The same 
amount of free tWGA did not show an equivalent strong effect on both pumping rate and area of 
DAergic neurons. Dose-dependent PLGA-tWGA NPs effects on DAergic neurons were proven 
to be stronger than that of free tWGA.  
A time study of number, size and area of neurons treated at concentration of NPs (3 
mg/ml for PLGA-t NPs and PLGA-tWGA NPs) and equivalent free tWGA concentration (15.0 
µg/ml for tWGA) were conducted, as well (Figure 3.8). Generally, number, area and intensity 
decreased during aging. However, except for area of PLGA-tWGA treated group compared with 
control (P=0.002), no significant difference was observed for the other treatments and parameters 
studied. Both tWGA and PLGA-t NPs did not cause significant effects on GFP-DAergic neurons 
in terms of number, area and intensity while PLGA-tWGA did. GFP-DAergic neurons studies 
along with time study indicated PLGA-tWGA NPs had significant effect especially at high 
concentrations (>3 mg/ml) on GFP-DAergic neurons. The significant changes observed in the 
area of neurons in PLGA-tWGA treated worms indicated that PLGA-tWGA NPs successfully 
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transported to DAergic neurons and showed a concentration-dependent effect on DAergic neuron 
cell. 
 
3.4.3.4.  Co-localization 
For all treatments (free WGA and WGA-conjugated NPs, all labeled with TRITC), a 
Zeiss LSM510 laser scanning microscope was used to confirm in vivo targeting and NP 
distribution. For PLGA-t NPs treated group, PLGA-t NPs were located along the mouth and 
intestine of worms while PLGA-tWGA NPs showed up less in the intestine (Figure 3.9).  
(a) (b) 
(c) 
Figure 3.8. (a) Number, (b) area 
and (c) intensity of GFP-





Very faint fluorescence was detected in the free tWGA treated worms over all 
concentrations tested as lectins might be readily digested or excreted out of the body. PLGA-
tWGA NPs were proved to co-localize with the GFP-DAergic neurons as indicated by green 
fluorescence partially overlapped with red fluorescence (labeled nanoparticles) (Figure 3.9c). 
(a) 
FITC Channel TRITC Channel Merged Channel 
(b) 
(c) 
   
Figure 3.9. Fluorescent pictures of (a) control group (×10), (b) 2.0 mg/ml PLGA-t 
NPs treated group (×10), and (c) 1.0 mg/ml PLGA-tWGA NPs treated group (×20). 






Co-localization was not observed in PLGA-t NPs treated group or most tWGA treated worms but 
only in PLGA-tWGA NPs treated groups, which demonstrated that tWGA conjugated to PLGA 
NPs were able to target neurons.  
N-acetyl-glucosamine and sialic acid are abundant on most cell surface including 
intestinal mucus and cerebral capillary endothelium (Bies, Lehr et al. 2004; Gabor, Bogner et al. 
2004) and are binding moieties of WGA. The interaction between the glycoproteins on cell 
surface and WGA was hypothesized to enhance cellular binding and endocytosis of WGA-
conjugated nanoparticles by receptor-mediated pathway (Bies, Lehr et al. 2004). Compared to 
PLGA-t NPs, PLGA-tWGA NPs showed stronger effect on both pumping rate and GFP-DAergic 
neurons, as expected. Co-localization pictures further confirmed that the conjugation of tWGA 
improved targeted transport of nanoparticles to DAergic neurons. Interestingly, when conjugated 
to NPs, transport ability of tWGA was greater than that of free tWGA. Significant decreasing in 
pumping rate and area of GFP-DAergic neurons with PLGA-tWGA NPs treatment indicated a 
higher effect on DAergic neurons of covalently linked tWGA over free tWGA. An in vitro study 
of transcytosis of WGA-conjugated NPs in Caco-2 cells also revealed that WGA-conjugated NPs 
had a higher transcytosis than free WGA (Russell-Jones, Veitch et al. 1999). The enhanced 
transcytosis could be due to a possibly different trafficking route of PLGA-tWGA NPs when 
compared to free tWGA or enhanced receptor clustering which was induced by multiple tWGA 
binding on the surface of nanoparticles (Russell-Jones, Veitch et al. 1999; Gabor, Bogner et al. 
2004). Similarly, more PLGA-tWGA NPs were possibly transcytosed into systemic circulation 
than free tWGA after PLGA-tWGA NPs in C.elegans from the intestine, and therefore provided 
a better chance to target DAergic neurons. Enhanced targeted delivery of PLGA-tWGA NPs to 
neurons compared with tWGA and PLGA-t NPs was confirmed in C.elegans, making PLGA-
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tWGA NPs ideal targeted neural delivery systems that could be used to deliver drugs to neurons 
and fight neurodegenerative disease such as Parkinson’s disease. 
3.5. Conclusion 
A DAergic neuron targeting delivery system was successfully constructed by conjugating 
tWGA with PLGA NPs. PLGA-tWGA polymer was synthesized first and then used to prepare 
nanoparticles of 221 nm (5 μg tWGA /mg NPs); nanoparticles were tested in C.elegans. PLGA-
tWGA NPs did not show a significant effect on pumping rate and life span of C. elegans at low 
concentration (<3 mg/ml). For tWGA treated worms, only the highest concentration resulted in a 
significant effect on pumping rate. Both length and width of C. elegans over all concentration of 
tWGA and PLGA-tWGA NPs treatment were only slightly affected. Due to the high 
concentration TRITC, PLGA-t NPs proved toxic to the worms at concentrations higher than 3 
mg/ml. Fluorescent studies of GFP-DAergic neurons revealed that area of GFP-DAergic neurons 
of worms treated with high concentrations PLGA-tWGA NPs (>3mg/ml) was significantly 
decreased. Number and mean intensity of GFP-DAergic neurons also decreased, but no 
significant difference was found compared with control group. WGA conjugated PLGA NPs at 
low concentrations (<3mg/ml) was proved to target DAergic neurons without negative effects. 
The decreasing values of GFP-DAergic neurons in terms of area and intensity along with the co-
localization of the fluorescent particles with the GFP-DAergic neurons of treated worms proved 
targeting property of PLGA-tWGA nanoparticles to DAergic neurons. However, the mechanism 
of tWGA transport to DAergic neurons when conjugated to PLGA NPs has not been thoroughly 
understood as a result of this study. Future studies should consider unveiling the mechanism of 
NPs uptake and transport to the neurons, as well as the effect of different sizes of nanoparticles 





Alves, G., E. B. Forsaa, et al. (2008). "Epidemiology of Parkinson's disease." J Neurol 255 
Suppl 5: 18-32. 
 
Bies, C., C. M. Lehr, et al. (2004). "Lectin-mediated drug targeting: history and applications." 
Adv Drug Deliv Rev 56(4): 425-435. 
 
Braungart, E., M. Gerlach, et al. (2004). "Caenorhabditis elegans MPP+ model of Parkinson's 
disease for high-throughput drug screenings." Neurodegener Dis 1(4-5): 175-183. 
 
Ceravolo, R., D. Frosini, et al. (2009). "Impulse control disorders in Parkinson's disease: 
definition, epidemiology, risk factors, neurobiology and management." Parkinsonism Relat 
Disord 15 Suppl 4: S111-115. 
 
Chang, J., Y. Jallouli, et al. (2009). "Characterization of endocytosis of transferrin-coated PLGA 
nanoparticles by the blood-brain barrier." Int J Pharm 379(2): 285-292. 
 
Chow, D. K., C. F. Glenn, et al. (2006). "Sarcopenia in the Caenorhabditis elegans pharynx 
correlates with muscle contraction rate over lifespan." Exp Gerontol 41(3): 252-260. 
 
Chung, Y. I., J. C. Kim, et al. (2010). "The effect of surface functionalization of PLGA 
nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting." J Control Release 
143(3): 374-382. 
 
Collins, J. J., C. Huang, et al. The measurement and analysis of age-related changes in 
Caenorhabditis elegans. WormBook. T. C. e. R. Community, WormBook. 
 
Factor, S. A. (2008). "Current status of symptomatic medical therapy in Parkinson's disease." 
Neurotherapeutics 5(2): 164-180. 
 
Gabor, F., E. Bogner, et al. (2004). "The lectin-cell interaction and its implications to intestinal 
lectin-mediated drug delivery." Adv Drug Deliv Rev 56(4): 459-480. 
 
Gao, X., B. Wu, et al. (2007). "Brain delivery of vasoactive intestinal peptide enhanced with the 
nanoparticles conjugated with wheat germ agglutinin following intranasal administration." J 
Control Release 121(3): 156-167. 
 
Hu, K., Y. Shi, et al. (2011). "Lactoferrin conjugated PEG-PLGA nanoparticles for brain 
delivery: preparation, characterization and efficacy in Parkinson's disease." Int J Pharm 415(1-2): 
273-283. 
 
Irache, J. M., C. Durrer, et al. (1994). "Preparation and characterization of lectin-latex conjugates 
for specific bioadhesion." Biomaterials 15(11): 899-904. 





Linazasoro, G. (2008). "Potential applications of nanotechnologies to Parkinson's disease 
therapy." Parkinsonism Relat Disord 14(5): 383-392. 
 
Liu, Y., P. Wang, et al. (2010). "Wheat germ agglutinin-grafted lipid nanoparticles: preparation 
and in vitro evaluation of the association with Caco-2 monolayers." Int J Pharm 397(1-2): 155-
163. 
 
Meyer, J. N., C. A. Lord, et al. (2010). "Intracellular uptake and associated toxicity of silver 
nanoparticles in Caenorhabditis elegans." Aquat Toxicol 100(2): 140-150. 
 
Mo, Y. and L. Y. Lim (2005). "Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer 
activity by surface conjugation with wheat germ agglutinin." J Control Release 108(2-3): 244-
262. 
 
Mo, Y. and L. Y. Lim (2005). "Preparation and in vitro anticancer activity of wheat germ 
agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl 
myristate." J Control Release 107(1): 30-42. 
 
Nass, R., D. H. Hall, et al. (2002). "Neurotoxin-induced degeneration of dopamine neurons in 
Caenorhabditis elegans." Proc Natl Acad Sci U S A 99(5): 3264-3269. 
 
Nass, R., K. M. Merchant, et al. (2008). "Caenohabditis elegans in Parkinson's disease drug 
discovery: addressing an unmet medical need." Mol Interv 8(6): 284-293. 
 
Ratzinger, G., X. Wang, et al. (2010). "Targeted PLGA microparticles as a novel concept for 
treatment of lactose intolerance." J Control Release 147(2): 187-192. 
 
Ravi Kumar, M. N. (2000). "Nano and microparticles as controlled drug delivery devices." J 
Pharm Pharm Sci 3(2): 234-258. 
 
Riddle, D. L. (1997). C. elegans II. Plainview, N.Y., Cold Spring Harbor Laboratory Press. 
 
Russell-Jones, G. J., H. Veitch, et al. (1999). "Lectin-mediated transport of nanoparticles across 
Caco-2 and OK cells." Int J Pharm 190(2): 165-174. 
 
Schapira, A. H. (2005). "Present and future drug treatment for Parkinson's disease." J Neurol 
Neurosurg Psychiatry 76(11): 1472-1478. 
 
So, S., K. Miyahara, et al. (2011). "Control of body size in C. elegans dependent on food and 
insulin/IGF-1 signal." Genes Cells 16(6): 639-651. 
 
Wang, C., P. C. Ho, et al. (2010). "Wheat germ agglutinin-conjugated PLGA nanoparticles for 





Wang, Z. H., Z. Y. Wang, et al. (2010). "Trimethylated chitosan-conjugated PLGA nanoparticles 
for the delivery of drugs to the brain." Biomaterials 31(5): 908-915. 
Weissenbock, A., M. Wirth, et al. (2004). "WGA-grafted PLGA-nanospheres: preparation and 
association with Caco-2 single cells." J Control Release 99(3): 383-392. 
 
Wen, Z., Z. Yan, et al. (2011). "Odorranalectin-conjugated nanoparticles: preparation, brain 
delivery and pharmacodynamic study on Parkinson's disease following intranasal 
administration." J Control Release 151(2): 131-138. 
 
Wintle, R. F. and H. H. Van Tol (2001). "Dopamine signaling in Caenorhabditis elegans-
potential for parkinsonism research." Parkinsonism Relat Disord 7(3): 177-183. 
 
Wolkow, C. A. (2006). "Identifying factors that promote functional aging in Caenorhabditis 
elegans." Exp Gerontol 41(10): 1001-1006. 
 
Wolters, E. (2009). "Non-motor extranigral signs and symptoms in Parkinson's disease." 
Parkinsonism Relat Disord 15 Suppl 3: S6-12. 
 
Wood, W. B. (1988). The Nematode Caenorhabditis elegans. Cold Spring Harbor, N.Y., Cold 
Spring Harbor Laboratory. 
 
Yin, Y., D. Chen, et al. (2006). "Preparation and evaluation of lectin-conjugated PLGA 
nanoparticles for oral delivery of thymopentin." J Control Release 116(3): 337-345. 
 
Zigoneanu, I. G., C. E. Astete, et al. (2008). "Nanoparticles with entrapped alpha-tocopherol: 







CHAPTER 4.    CONCLUSION  
In recent years, polymeric nanoparticles were well investigated and the technology has 
developed at a rapid pace. PLGA/PLA nanoparticles (100-300 nm) have been proven as potential 
carriers for drug delivery across the BBB with advantages of both enhanced drug efficiency and 
safety. Both in vitro and in vivo studies on delivery of drugs with surface modified PLGA/PLA 
NPs (100-300 nm) to CNS confirmed the enhanced brain uptake and therapeutic efficacy of 
certain drugs entrapped in PLGA NPs.  
A DAergic neuron targeting delivery system was successfully constructed by conjugating 
tWGA with PLGA NPs. PLGA-tWGA polymer was synthesized first and then used to prepare 
nanoparticles of 221 nm (5 μg tWGA /mg NPs). The following tests in C.elegans showed that 
PLGA-tWGA NPs did not have significant effect on pumping rate and life span of C.elegans as 
low concentration (<3 mg/ml). Fluorescent studies of GFP-DAergic neurons revealed that area of 
GFP-DAergic neurons of worms treated with high concentrations PLGA-tWGA NPs (>3mg/ml) 
was significantly decreased. Number and mean intensity of GFP-DAergic neurons also decreased, 
but no significant difference was found compared with control group. The co-localization of 
PLGA-tWGA NPs with the GFP-DAergic neurons of treated worms along with locomotion and 
neuron studies of C.elegans proved that WGA conjugated PLGA NPs at low concentrations 
(<3mg/ml) targeted DAergic neurons without negative effects.   
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CHAPTER 5.    FUTURE WORK 
The mechanism of tWGA transport to DAergic neurons when conjugated to PLGA NPs 
has not been thoroughly understood as a result of this study. Future studies should consider 
unveiling the mechanism of NPs uptake and transport to the neurons, as well as the effect of 
different sizes of nanoparticles and different amounts of tWGA on targeting neurons in C. 
elegans. Furthermore, PLGA-tWGA NPs with entrapped L-DOPA should be synthesized and 
investigated for the drug efficacy in C.elegans.  Other animal studies such as mice or rats should 
also be considered to determine the ability of PLGA-tWGA NPs cross the BBB. It is necessary 
to assess the safety and potential risks of PLGA-tWGA NPs in vertebrate especially after long-




APPENDIX.  STANDARD CURVES 
1. Standard Curve for WGA 
The conjugation efficiency of PLGA-tWGA NPs was determined by BCA protein 
assay (BCA protein assay kit, Thermo Scientific, Rockford, IL, USA) (Mo and Lim 2005). 
An enhanced test tube protocol with working range at 5-250 µg/ml was used. A series of 
albumin (BSA) solutions were prepared for a standard curve. The volume of 0.1 ml of each 
standard BSA solution, PLGA-tWGA solution were pipetted to each labeled tube, and 2.0 ml 
freshly prepared BCA working reagent was added to each tube. The mixtures were incubated 
at 60 °C for 30 minutes, and cooled to room temperature. The absorbance of all samples was 
measured with a spectrophotometer set at 562 nm within 10 minutes. A cuvette filled only 




Figure A.1. Standard curve for WGA 
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2. Standard Curve for TRITC 
The amount of TRITC conjugated to PLGA-t NPs was determined by using a 
spectrofluorometer (Wallac 1420 VICTOR, Perkin Elmer Inc., Waltham, Massachusetts, USA). 
The volume of 0.1 mL standard TRITC solution was pipetted to each well. The intensity of the 
standard solution was measured at different concentrations at the absorbance 531/572 nm with 
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